ID

DB00247|APRD00463||

名称

Methysergide

描述

An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.

cas号

361-37-5

唯一标识码

XZA9HY6Z98

状态

solid

组

approved,

指示

For the treatment of vascular headache

药效学

Methysergide has been shown, in vitro and in vivo, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of vascular headaches. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a "headache substance" acting directly or indirectly to lower pain threshold, as an intrinsic "motor hormone" of the gastrointestinal tract, and as a "hormone" involved in connective tissue reparative processes.

作用机制

Methysergide is serotonin antagonists acts on central nervous system (CNS), which directly stimulates the smooth muscle leading to vasoconstriction. Some alpha-adrenergic blocking activity has been reported. Suggestions have been made by investigators as to the mechanism whereby Methysergide produces its clinical effects, but this has not been finally established, although it may be related to the antiserotonin effect.

毒性

Few cases of acute methysergide intoxication have been reported. The possible symptom complex is therefore not fully known. The following symptoms are based on these few case reports. Euphoria, hyperactivity, tachycardia, dilated pupils, and dizziness have been reported in a child with a dose of 20-24 mg of methysergide. In adults, peripheral vasospasm, with diminished or absent pulses, coldness, mottling and cyanosis, has been observed at a dose of 200 mg. Ischemic tissue damage has not been reported in acute overdosage with methysergide.

代谢

Hepatic

吸收

Rapid

半衰期

分类

description:This compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
direct-parent:Lysergamides
kingdom:Organic compounds
superclass:Alkaloids and derivatives
class:Ergoline and derivatives
subclass:Lysergic acids and derivatives
alternative-parent:3-alkylindoles
alternative-parent:Amino acids and derivatives
alternative-parent:Aralkylamines
alternative-parent:Azacyclic compounds
alternative-parent:Benzenoids
alternative-parent:Benzoquinolines
alternative-parent:Carbonyl compounds
alternative-parent:Heteroaromatic compounds
alternative-parent:Hydrocarbon derivatives
alternative-parent:Indoloquinolines
alternative-parent:Isoindoles and derivatives
alternative-parent:N-alkylindoles
alternative-parent:N-methylpyrroles
alternative-parent:Organic oxides
alternative-parent:Organopnictogen compounds
alternative-parent:Primary alcohols
alternative-parent:Pyrroloquinolines
alternative-parent:Quinoline-3-carboxamides
alternative-parent:Secondary carboxylic acid amides
alternative-parent:Trialkylamines
substituent:3-alkylindole
substituent:Alcohol
substituent:Amine
substituent:Amino acid or derivatives
substituent:Aralkylamine
substituent:Aromatic heteropolycyclic compound
substituent:Azacycle
substituent:Benzenoid
substituent:Benzoquinoline
substituent:Carbonyl group
substituent:Carboxamide group
substituent:Carboxylic acid derivative
substituent:Heteroaromatic compound
substituent:Hydrocarbon derivative
substituent:Indole
substituent:Indole or derivatives
substituent:Indoloquinoline
substituent:Isoindole or derivatives
substituent:Lysergic acid amide
substituent:N-alkylindole
substituent:N-methylpyrrole
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organoheterocyclic compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Primary alcohol
substituent:Pyrrole
substituent:Pyrroloquinoline
substituent:Quinoline
substituent:Quinoline-3-carboxamide
substituent:Secondary carboxylic acid amide
substituent:Substituted pyrrole
substituent:Tertiary aliphatic amine
substituent:Tertiary amine

消除途径

种类

Agents that produce hypertension

Alkaloids
D000470
Analgesics
D000700
Antidepressive Agents
D000928
Antimigraine Preparations

Cardiovascular Agents
D002317
Central Nervous System Depressants
D002492
Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 CYP3A4 Substrates (strength unknown)

Cytochrome P-450 Substrates

Ergolines
D004873
Ergot Alkaloids and Derivatives
D004876
Heterocyclic Compounds, Fused-Ring
D000072471
Lysergic Acid
D008237
Nervous System
D009420
Neurotransmitter Agents
D018377
Serotonin 5-HT2 Receptor Antagonists
D058830
Serotonin 5-HT2A Receptor Antagonists
D058830
Serotonin 5-HT2C Receptor Antagonists
D058830
Serotonin Agents
D018490
Serotonin Receptor Antagonists
D012702
Vasoconstrictor Agents
D014662

盐类

DBSALT000895Methysergide maleate2U7H1466GH129-49-7LWYXFDXUMVEZKS-ZVFOLQIPSA-N469.538469.22128573

蛋白质结合

清除

同义词

language:english; code:; name;(+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8β-carboxamide
language:english; code:; name;(+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide
language:english; code:; name;1-Methyl-D-lysergic acid butanolamide
language:english; code:; name;1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide
language:english; code:; name;1-Methyllysergic acid butanolamide
language:english; code:; name;1-Methylmethylergonovine
language:english; code:; name;9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
language:french; code:inn; name;Méthysergide
language:english; code:inn; name;Methysergide
language:latin; code:inn; name;Methysergidum
language:spanish; code:inn; name;Metisergida
language:spanish; code:; name;Metisergido
language:english; code:; name;N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide

国际品牌

DeserilDesernil

配送量

产品

name:Sansert
labeller:Novartis
ndc-id:
ndc-product-code:0078-0058
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1962-02-12
ended-marketing-on:2008-09-17
dosage-form:Tablet, coated
strength:2 mg/1
route:Oral
fda-application-number:NDA012516
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sansert
labeller:Novartis
ndc-id:
ndc-product-code:
dpd-id:00027499
ema-product-code:
ema-ma-number:
started-marketing-on:1962-12-31
ended-marketing-on:2009-02-16
dosage-form:Tablet
strength:2 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD

混合物

name:Sansert
ingredients:Methysergide
name:Sansert
ingredients:Methysergide

包装者

name:Novartis AG
url:http://www.novartis.com
name:Pharmaceutical Utilization Management Program VA Inc.
url:
name:Professional Co.
url:

生产者

generic:否; url:; name;Novartis pharmaceuticals corp

价格

Desyrel 100 mg tablet
4.26(单位：USD）
tablet
Methysergide maleate 100% powder
2580.0(单位：USD）
g

受影响的生物体

Humans and other mammals

剂量

form:Pill
route:
strength:1.4 MG
form:Tablet
route:Oral
strength:2 mg
form:Tablet, coated
route:Oral
strength:2 mg/1

atc代码

Ergot alkaloids
ANTIMIGRAINE PREPARATIONS
ANALGESICS
NERVOUS SYSTEM

fda标签

化学品安全技术说明书

专利

食物相互作用

Take with food. Food reduces irritation.

药物相互作用

DB00252
The metabolism of Methysergide can be increased when combined with Phenytoin.
DB01320
The metabolism of Methysergide can be increased when combined with Fosphenytoin.
DB00177
Methysergide may decrease the antihypertensive activities of Valsartan.
DB00178
Methysergide may decrease the antihypertensive activities of Ramipril.
DB00212
Methysergide may decrease the antihypertensive activities of Remikiren.
DB00214
Methysergide may decrease the antihypertensive activities of Torasemide.
DB00226
Methysergide may decrease the antihypertensive activities of Guanadrel.
DB00275
Methysergide may decrease the antihypertensive activities of Olmesartan.
DB00310
Methysergide may decrease the antihypertensive activities of Chlorthalidone.
DB00325
Methysergide may decrease the antihypertensive activities of Nitroprusside.
DB00350
Methysergide may decrease the antihypertensive activities of Minoxidil.
DB00374
Methysergide may decrease the antihypertensive activities of Treprostinil.
DB00436
Methysergide may decrease the antihypertensive activities of Bendroflumethiazide.
DB00457
Methysergide may decrease the antihypertensive activities of Prazosin.
DB00492
Methysergide may decrease the antihypertensive activities of Fosinopril.
DB00519
Methysergide may decrease the antihypertensive activities of Trandolapril.
DB00524
Methysergide may decrease the antihypertensive activities of Metolazone.
DB00542
Methysergide may decrease the antihypertensive activities of Benazepril.
DB00606
Methysergide may decrease the antihypertensive activities of Cyclothiazide.
DB00616
Methysergide may decrease the antihypertensive activities of Candoxatril.
DB00657
Methysergide may decrease the antihypertensive activities of Mecamylamine.
DB00691
Methysergide may decrease the antihypertensive activities of Moexipril.
DB00722
Methysergide may decrease the antihypertensive activities of Lisinopril.
DB00774
Methysergide may decrease the antihypertensive activities of Hydroflumethiazide.
DB00785
Methysergide may decrease the antihypertensive activities of Cryptenamine.
DB00790
Methysergide may decrease the antihypertensive activities of Perindopril.
DB00796
Methysergide may decrease the antihypertensive activities of Candesartan cilexetil.
DB00800
Methysergide may decrease the antihypertensive activities of Fenoldopam.
DB00876
Methysergide may decrease the antihypertensive activities of Eprosartan.
DB00880
Methysergide may decrease the antihypertensive activities of Chlorothiazide.
DB00881
Methysergide may decrease the antihypertensive activities of Quinapril.
DB00966
Methysergide may decrease the antihypertensive activities of Telmisartan.
DB00999
Methysergide may decrease the antihypertensive activities of Hydrochlorothiazide.
DB01021
Methysergide may decrease the antihypertensive activities of Trichlormethiazide.
DB01089
Methysergide may decrease the antihypertensive activities of Deserpidine.
DB01090
Methysergide may decrease the antihypertensive activities of Pentolinium.
DB01116
Methysergide may decrease the antihypertensive activities of Trimethaphan.
DB01119
Methysergide may decrease the antihypertensive activities of Diazoxide.
DB01158
Methysergide may decrease the antihypertensive activities of Bretylium.
DB01162
Methysergide may decrease the antihypertensive activities of Terazosin.
DB01197
Methysergide may decrease the antihypertensive activities of Captopril.
DB01240
Methysergide may decrease the antihypertensive activities of Epoprostenol.
DB01324
Methysergide may decrease the antihypertensive activities of Polythiazide.
DB01340
Methysergide may decrease the antihypertensive activities of Cilazapril.
DB01347
Methysergide may decrease the antihypertensive activities of Saprisartan.
DB01348
Methysergide may decrease the antihypertensive activities of Spirapril.
DB04831
Methysergide may decrease the antihypertensive activities of Tienilic acid.
DB04840
Methysergide may decrease the antihypertensive activities of Debrisoquine.
DB06445
Methysergide may decrease the antihypertensive activities of Diethylnorspermine.
DB07767
Methysergide may decrease the antihypertensive activities of Ferulic acid.
DB08836
Methysergide may decrease the antihypertensive activities of Temocapril.
DB09206
Methysergide may decrease the antihypertensive activities of Trimazosin.
DB09220
Methysergide may decrease the antihypertensive activities of Nicorandil.
DB09363
Methysergide may decrease the antihypertensive activities of Rauwolfia serpentina root.
DB09477
Methysergide may decrease the antihypertensive activities of Enalaprilat.
DB11720
Methysergide may decrease the antihypertensive activities of Angiotensin 1-7.
DB11783
Methysergide may decrease the antihypertensive activities of Imidapril.
DB12054
Methysergide may decrease the antihypertensive activities of BQ-123.
DB12766
Methysergide may decrease the antihypertensive activities of Cicletanine.
DB12945
Methysergide may decrease the antihypertensive activities of Dihydralazine.
DB13166
Methysergide may decrease the antihypertensive activities of Zofenopril.
DB13211
Methysergide may decrease the antihypertensive activities of Guanoxan.
DB13312
Methysergide may decrease the antihypertensive activities of Delapril.
DB13374
Methysergide may decrease the antihypertensive activities of Vincamine.
DB13400
Methysergide may decrease the antihypertensive activities of Linsidomine.
DB13410
Methysergide may decrease the antihypertensive activities of Guanoxabenz.
DB13429
Methysergide may decrease the antihypertensive activities of Tolonidine.
DB13435
Methysergide may decrease the antihypertensive activities of Endralazine.
DB13452
Methysergide may decrease the antihypertensive activities of Cadralazine.
DB13532
Methysergide may decrease the antihypertensive activities of Cyclopenthiazide.
DB13575
Methysergide may decrease the antihypertensive activities of Bietaserpine.
DB13604
Methysergide may decrease the antihypertensive activities of Guanazodine.
DB13631
Methysergide may decrease the antihypertensive activities of Methoserpidine.
DB13779
Methysergide may decrease the antihypertensive activities of Guanoclor.
DB13801
Methysergide may decrease the antihypertensive activities of Muzolimine.
DB13803
Methysergide may decrease the antihypertensive activities of Xipamide.
DB13919
Methysergide may decrease the antihypertensive activities of Candesartan.
DB14094
Methysergide may decrease the antihypertensive activities of Tocopherylquinone.
DB14125
Methysergide may decrease the antihypertensive activities of Benazeprilat.
DB14207
Methysergide may decrease the antihypertensive activities of Fosinoprilat.
DB14208
Methysergide may decrease the antihypertensive activities of Ramiprilat.
DB14213
Methysergide may decrease the antihypertensive activities of Perindoprilat.
DB14217
Methysergide may decrease the antihypertensive activities of Quinaprilat.
DB00695
Methysergide may decrease the antihypertensive activities of Furosemide.
DB00584
Methysergide may decrease the antihypertensive activities of Enalapril.
DB00381
Methysergide may decrease the antihypertensive activities of Amlodipine.
DB00393
Methysergide may decrease the antihypertensive activities of Nimodipine.
DB00528
Methysergide may decrease the antihypertensive activities of Lercanidipine.
DB00808
Methysergide may decrease the antihypertensive activities of Indapamide.
DB01054
Methysergide may decrease the antihypertensive activities of Nitrendipine.
DB01170
Methysergide may decrease the antihypertensive activities of Guanethidine.
DB01244
Methysergide may decrease the antihypertensive activities of Bepridil.
DB06403
Methysergide may decrease the antihypertensive activities of Ambrisentan.
DB06762
Methysergide may decrease the antihypertensive activities of Pinacidil.
DB08931
Methysergide may decrease the antihypertensive activities of Riociguat.
DB08932
Methysergide may decrease the antihypertensive activities of Macitentan.
DB09026
Methysergide may decrease the antihypertensive activities of Aliskiren.
DB09236
Methysergide may decrease the antihypertensive activities of Lacidipine.
DB09239
Methysergide may decrease the antihypertensive activities of Niguldipine.
DB11362
Methysergide may decrease the antihypertensive activities of Selexipag.
DB12092
Methysergide may decrease the antihypertensive activities of Naftopidil.
DB14068
Methysergide may decrease the antihypertensive activities of Dexniguldipine.
DB00820
Methysergide may decrease the antihypertensive activities of Tadalafil.
DB00401
Methysergide may decrease the antihypertensive activities of Nisoldipine.
DB00700
Methysergide may decrease the antihypertensive activities of Eplerenone.
DB09238
Methysergide may decrease the antihypertensive activities of Manidipine.
DB09237
Methysergide may decrease the antihypertensive activities of Levamlodipine.
DB00921
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB00470
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB00450
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB00956
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DB00557
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB00653
The therapeutic efficacy of Methysergide can be increased when used in combination with Magnesium sulfate.
DB01403
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DB00765
Methysergide may increase the sedative activities of Metyrosine.
DB01017
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB00370
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DB00486
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB01173
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DB09117
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
DB08883
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB00413
Methysergide may increase the sedative activities of Pramipexole.
DB00268
Methysergide may increase the sedative activities of Ropinirole.
DB05271
Methysergide may increase the sedative activities of Rotigotine.
DB06201
The risk or severity of adverse effects can be increased when Rufinamide is combined with Methysergide.
DB09072
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB09034
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
DB06204
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB01041
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DB00425
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DB00035
The risk or severity of hypertension can be increased when Desmopressin is combined with Methysergide.
DB00159
The risk or severity of hypertension can be increased when Icosapent is combined with Methysergide.
DB00244
The risk or severity of hypertension can be increased when Mesalazine is combined with Methysergide.
DB00328
The risk or severity of hypertension can be increased when Methysergide is combined with Indomethacin.
DB00422
The risk or severity of hypertension can be increased when Methysergide is combined with Methylphenidate.
DB00461
The risk or severity of hypertension can be increased when Methysergide is combined with Nabumetone.
DB00465
The risk or severity of hypertension can be increased when Methysergide is combined with Ketorolac.
DB00469
The risk or severity of hypertension can be increased when Methysergide is combined with Tenoxicam.
DB00500
The risk or severity of hypertension can be increased when Methysergide is combined with Tolmetin.
DB00554
The risk or severity of hypertension can be increased when Methysergide is combined with Piroxicam.
DB00561
The risk or severity of hypertension can be increased when Methysergide is combined with Doxapram.
DB00573
The risk or severity of hypertension can be increased when Methysergide is combined with Fenoprofen.
DB00605
The risk or severity of hypertension can be increased when Methysergide is combined with Sulindac.
DB00692
The risk or severity of hypertension can be increased when Methysergide is combined with Phentolamine.
DB00699
The risk or severity of hypertension can be increased when Methysergide is combined with Nicergoline.
DB00712
The risk or severity of hypertension can be increased when Methysergide is combined with Flurbiprofen.
DB00749
The risk or severity of hypertension can be increased when Methysergide is combined with Etodolac.
DB00784
The risk or severity of hypertension can be increased when Methysergide is combined with Mefenamic acid.
DB00788
The risk or severity of hypertension can be increased when Methysergide is combined with Naproxen.
DB00795
The risk or severity of hypertension can be increased when Methysergide is combined with Sulfasalazine.
DB00797
The risk or severity of hypertension can be increased when Methysergide is combined with Tolazoline.
DB00821
The risk or severity of hypertension can be increased when Methysergide is combined with Carprofen.
DB00830
The risk or severity of hypertension can be increased when Methysergide is combined with Phenmetrazine.
DB00861
The risk or severity of hypertension can be increased when Methysergide is combined with Diflunisal.
DB00886
The risk or severity of hypertension can be increased when Methysergide is combined with Omapatrilat.
DB00925
The risk or severity of hypertension can be increased when Methysergide is combined with Phenoxybenzamine.
DB00936
The risk or severity of hypertension can be increased when Methysergide is combined with Salicylic acid.
DB00939
The risk or severity of hypertension can be increased when Methysergide is combined with Meclofenamic acid.
DB00945
The risk or severity of hypertension can be increased when Methysergide is combined with Acetylsalicylic acid.
DB00988
The risk or severity of hypertension can be increased when Methysergide is combined with Dopamine.
DB00991
The risk or severity of hypertension can be increased when Methysergide is combined with Oxaprozin.
DB01009
The risk or severity of hypertension can be increased when Methysergide is combined with Ketoprofen.
DB01014
The risk or severity of hypertension can be increased when Methysergide is combined with Balsalazide.
DB01180
The risk or severity of hypertension can be increased when Methysergide is combined with Rescinnamine.
DB01250
The risk or severity of hypertension can be increased when Methysergide is combined with Olsalazine.
DB01255
The risk or severity of hypertension can be increased when Methysergide is combined with Lisdexamfetamine.
DB01283
The risk or severity of hypertension can be increased when Methysergide is combined with Lumiracoxib.
DB01397
The risk or severity of hypertension can be increased when Methysergide is combined with Magnesium salicylate.
DB01399
The risk or severity of hypertension can be increased when Methysergide is combined with Salsalate.
DB01401
The risk or severity of hypertension can be increased when Methysergide is combined with Choline magnesium trisalicylate.
DB01419
The risk or severity of hypertension can be increased when Methysergide is combined with Antrafenine.
DB01467
The risk or severity of hypertension can be increased when Methysergide is combined with 2,5-Dimethoxy-4-ethylamphetamine.
DB01556
The risk or severity of hypertension can be increased when Methysergide is combined with Chlorphentermine.
DB01576
The risk or severity of hypertension can be increased when Methysergide is combined with Dextroamphetamine.
DB01600
The risk or severity of hypertension can be increased when Methysergide is combined with Tiaprofenic acid.
DB02032
The risk or severity of hypertension can be increased when Methysergide is combined with Epicaptopril.
DB02224
The risk or severity of hypertension can be increased when Methysergide is combined with Taxifolin.
DB03585
The risk or severity of hypertension can be increased when Methysergide is combined with Oxyphenbutazone.
DB04581
The risk or severity of hypertension can be increased when Methysergide is combined with 1-benzylimidazole.
DB04812
The risk or severity of hypertension can be increased when Methysergide is combined with Benoxaprofen.
DB05095
The risk or severity of hypertension can be increased when Methysergide is combined with Cimicoxib.
DB06725
The risk or severity of hypertension can be increased when Methysergide is combined with Lornoxicam.
DB06736
The risk or severity of hypertension can be increased when Methysergide is combined with Aceclofenac.
DB06737
The risk or severity of hypertension can be increased when Methysergide is combined with Zaltoprofen.
DB06763
The risk or severity of hypertension can be increased when Methysergide is combined with Saralasin.
DB07402
The risk or severity of hypertension can be increased when Methysergide is combined with Azapropazone.
DB08797
The risk or severity of hypertension can be increased when Methysergide is combined with Salicylamide.
DB08841
The risk or severity of hypertension can be increased when Methysergide is combined with Tyramine.
DB08940
The risk or severity of hypertension can be increased when Methysergide is combined with Kebuzone.
DB08942
The risk or severity of hypertension can be increased when Methysergide is combined with Isoxicam.
DB08950
The risk or severity of hypertension can be increased when Methysergide is combined with Indoramin.
DB08951
The risk or severity of hypertension can be increased when Methysergide is combined with Indoprofen.
DB08955
The risk or severity of hypertension can be increased when Methysergide is combined with Ibuproxam.
DB08976
The risk or severity of hypertension can be increased when Methysergide is combined with Floctafenine.
DB08981
The risk or severity of hypertension can be increased when Methysergide is combined with Fenbufen.
DB08984
The risk or severity of hypertension can be increased when Methysergide is combined with Etofenamate.
DB08991
The risk or severity of hypertension can be increased when Methysergide is combined with Epirizole.
DB09084
The risk or severity of hypertension can be increased when Methysergide is combined with Benzydamine.
DB09205
The risk or severity of hypertension can be increased when Methysergide is combined with Moxisylyte.
DB09213
The risk or severity of hypertension can be increased when Methysergide is combined with Dexibuprofen.
DB09214
The risk or severity of hypertension can be increased when Methysergide is combined with Dexketoprofen.
DB09215
The risk or severity of hypertension can be increased when Methysergide is combined with Droxicam.
DB09217
The risk or severity of hypertension can be increased when Methysergide is combined with Firocoxib.
DB09218
The risk or severity of hypertension can be increased when Methysergide is combined with Clonixin.
DB09285
The risk or severity of hypertension can be increased when Methysergide is combined with Morniflumate.
DB09295
The risk or severity of hypertension can be increased when Methysergide is combined with Talniflumate.
DB09480
The risk or severity of hypertension can be increased when Methysergide is combined with Iofetamine I-123.
DB11455
The risk or severity of hypertension can be increased when Methysergide is combined with Robenacoxib.
DB11466
The risk or severity of hypertension can be increased when Methysergide is combined with Tepoxalin.
DB11481
The risk or severity of hypertension can be increased when Methysergide is combined with Atipamezole.
DB11518
The risk or severity of hypertension can be increased when Methysergide is combined with Flunixin.
DB12445
The risk or severity of hypertension can be increased when Methysergide is combined with Nitroaspirin.
DB12545
The risk or severity of hypertension can be increased when Methysergide is combined with Indobufen.
DB12551
The risk or severity of hypertension can be increased when Methysergide is combined with Idazoxan.
DB12610
The risk or severity of hypertension can be increased when Methysergide is combined with Ebselen.
DB13001
The risk or severity of hypertension can be increased when Methysergide is combined with Tinoridine.
DB13064
The risk or severity of hypertension can be increased when Methysergide is combined with Tramazoline.
DB13108
The risk or severity of hypertension can be increased when Methysergide is combined with Mephedrone.
DB13167
The risk or severity of hypertension can be increased when Methysergide is combined with Alclofenac.
DB13217
The risk or severity of hypertension can be increased when Methysergide is combined with Fentiazac.
DB13232
The risk or severity of hypertension can be increased when Methysergide is combined with Suxibuzone.
DB13286
The risk or severity of hypertension can be increased when Methysergide is combined with Bumadizone.
DB13314
The risk or severity of hypertension can be increased when Methysergide is combined with Alminoprofen.
DB13341
The risk or severity of hypertension can be increased when Methysergide is combined with Fenozolone.
DB13371
The risk or severity of hypertension can be increased when Methysergide is combined with Difenpiramide.
DB13407
The risk or severity of hypertension can be increased when Methysergide is combined with Nifenazone.
DB13432
The risk or severity of hypertension can be increased when Methysergide is combined with Lonazolac.
DB13453
The risk or severity of hypertension can be increased when Methysergide is combined with Xenon.
DB13481
The risk or severity of hypertension can be increased when Methysergide is combined with Tenidap.
DB13510
The risk or severity of hypertension can be increased when Methysergide is combined with Buflomedil.
DB13524
The risk or severity of hypertension can be increased when Methysergide is combined with Propyphenazone.
DB13527
The risk or severity of hypertension can be increased when Methysergide is combined with Proglumetacin.
DB13538
The risk or severity of hypertension can be increased when Methysergide is combined with Guacetisal.
DB13544
The risk or severity of hypertension can be increased when Methysergide is combined with Ethenzamide.
DB13612
The risk or severity of hypertension can be increased when Methysergide is combined with Carbaspirin calcium.
DB13629
The risk or severity of hypertension can be increased when Methysergide is combined with Mofebutazone.
DB13649
The risk or severity of hypertension can be increased when Methysergide is combined with Proquazone.
DB13657
The risk or severity of hypertension can be increased when Methysergide is combined with Benorilate.
DB13703
The risk or severity of hypertension can be increased when Methysergide is combined with Gepefrine.
DB13722
The risk or severity of hypertension can be increased when Methysergide is combined with Pirprofen.
DB13783
The risk or severity of hypertension can be increased when Methysergide is combined with Acemetacin.
DB13852
The risk or severity of hypertension can be increased when Methysergide is combined with Mefenorex.
DB13860
The risk or severity of hypertension can be increased when Methysergide is combined with Imidazole salicylate.
DB14059
The risk or severity of hypertension can be increased when Methysergide is combined with SC-236.
DB14060
The risk or severity of hypertension can be increased when Methysergide is combined with NS-398.
DB14231
The risk or severity of hypertension can be increased when Methysergide is combined with Quinoline Yellow WS.
DB01126
The risk or severity of hypertension can be increased when Methysergide is combined with Dutasteride.
DB00482
The risk or severity of hypertension can be increased when Methysergide is combined with Celecoxib.
DB00580
The risk or severity of hypertension can be increased when Methysergide is combined with Valdecoxib.
DB00586
The risk or severity of hypertension can be increased when Methysergide is combined with Diclofenac.
DB00814
The risk or severity of hypertension can be increased when Methysergide is combined with Meloxicam.
DB01050
The risk or severity of hypertension can be increased when Methysergide is combined with Ibuprofen.
DB01216
The risk or severity of hypertension can be increased when Methysergide is combined with Finasteride.
DB01424
The risk or severity of hypertension can be increased when Methysergide is combined with Aminophenazone.
DB01435
The risk or severity of hypertension can be increased when Methysergide is combined with Antipyrine.
DB04743
The risk or severity of hypertension can be increased when Methysergide is combined with Nimesulide.
DB04828
The risk or severity of hypertension can be increased when Methysergide is combined with Zomepirac.
DB08439
The risk or severity of hypertension can be increased when Methysergide is combined with Parecoxib.
DB09216
The risk or severity of hypertension can be increased when Methysergide is combined with Tolfenamic acid.
DB09288
The risk or severity of hypertension can be increased when Methysergide is combined with Propacetamol.
DB13399
The risk or severity of hypertension can be increased when Methysergide is combined with Terguride.
DB00490
The risk or severity of hypertension can be increased when Methysergide is combined with Buspirone.
DB15685
The risk or severity of hypertension can be increased when Methysergide is combined with Selpercatinib.
DB09212
The risk or severity of hypertension can be increased when Methysergide is combined with Loxoprofen.
DB15965
The risk or severity of hypertension can be increased when Methysergide is combined with Naxitamab.
DB04871
The risk or severity of adverse effects can be increased when Lorcaserin is combined with Methysergide.
DB00727
The bioavailability of Methysergide can be increased when combined with Nitroglycerin.
DB08873
The risk or severity of adverse effects can be increased when Boceprevir is combined with Methysergide.
DB00834
The serum concentration of Methysergide can be increased when it is combined with Mifepristone.
DB00333
The risk or severity of adverse effects can be increased when Methadone is combined with Methysergide.
DB00266
The risk or severity of adverse effects can be increased when Methysergide is combined with Dicoumarol.
DB00498
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenindione.
DB04665
The risk or severity of adverse effects can be increased when Methysergide is combined with Coumarin.
DB13451
The risk or severity of adverse effects can be increased when Methysergide is combined with Tioclomarol.
DB08496
The risk or severity of adverse effects can be increased when Methysergide is combined with (R)-warfarin.
DB14055
The risk or severity of adverse effects can be increased when Methysergide is combined with (S)-Warfarin.
DB08794
The risk or severity of adverse effects can be increased when Methysergide is combined with Ethyl biscoumacetate.
DB13347
The risk or severity of adverse effects can be increased when Methysergide is combined with Diphenadione.
DB03410
The risk or severity of adverse effects can be increased when Methysergide is combined with 4-hydroxycoumarin.
DB13136
The risk or severity of adverse effects can be increased when Methysergide is combined with Fluindione.
DB13275
The risk or severity of adverse effects can be increased when Methysergide is combined with Clorindione.
DB01211
The serum concentration of Methysergide can be increased when it is combined with Clarithromycin.
DB01263
The serum concentration of Methysergide can be increased when it is combined with Posaconazole.
DB09065
The serum concentration of Methysergide can be increased when it is combined with Cobicistat.
DB00898
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
DB00972
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DB00484
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB12693
The risk or severity of adverse effects can be increased when Methysergide is combined with Ritanserin.
DB13233
The risk or severity of adverse effects can be increased when Methysergide is combined with Alaproclate.
DB00656
The risk or severity of adverse effects can be increased when Trazodone is combined with Methysergide.
DB01105
The risk or severity of adverse effects can be increased when Sibutramine is combined with Methysergide.
DB01175
The risk or severity of adverse effects can be increased when Escitalopram is combined with Methysergide.
DB08918
The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Methysergide.
DB00176
The risk or severity of adverse effects can be increased when Methysergide is combined with Fluvoxamine.
DB00215
The risk or severity of adverse effects can be increased when Methysergide is combined with Citalopram.
DB00476
The risk or severity of adverse effects can be increased when Methysergide is combined with Duloxetine.
DB00715
The risk or severity of adverse effects can be increased when Methysergide is combined with Paroxetine.
DB04832
The risk or severity of adverse effects can be increased when Methysergide is combined with Zimelidine.
DB04884
The risk or severity of adverse effects can be increased when Methysergide is combined with Dapoxetine.
DB04896
The risk or severity of adverse effects can be increased when Methysergide is combined with Milnacipran.
DB06700
The risk or severity of adverse effects can be increased when Methysergide is combined with Desvenlafaxine.
DB06731
The risk or severity of adverse effects can be increased when Methysergide is combined with Seproxetine.
DB08953
The risk or severity of adverse effects can be increased when Methysergide is combined with Indalpine.
DB00211
Methysergide may increase the hypertensive and vasoconstricting activities of Midodrine.
DB00217
Methysergide may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00221
Methysergide may increase the hypertensive and vasoconstricting activities of Isoetharine.
DB00292
Methysergide may increase the hypertensive and vasoconstricting activities of Etomidate.
DB00368
Methysergide may increase the hypertensive and vasoconstricting activities of Norepinephrine.
DB00388
Methysergide may increase the hypertensive and vasoconstricting activities of Phenylephrine.
DB00397
Methysergide may increase the hypertensive and vasoconstricting activities of Phenylpropanolamine.
DB00610
Methysergide may increase the hypertensive and vasoconstricting activities of Metaraminol.
DB00629
Methysergide may increase the hypertensive and vasoconstricting activities of Guanabenz.
DB00633
Methysergide may increase the hypertensive and vasoconstricting activities of Dexmedetomidine.
DB00697
Methysergide may increase the hypertensive and vasoconstricting activities of Tizanidine.
DB00723
Methysergide may increase the hypertensive and vasoconstricting activities of Methoxamine.
DB00816
Methysergide may increase the hypertensive and vasoconstricting activities of Orciprenaline.
DB00841
Methysergide may increase the hypertensive and vasoconstricting activities of Dobutamine.
DB00852
Methysergide may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.
DB00867
Methysergide may increase the hypertensive and vasoconstricting activities of Ritodrine.
DB00871
Methysergide may increase the hypertensive and vasoconstricting activities of Terbutaline.
DB00901
Methysergide may increase the hypertensive and vasoconstricting activities of Bitolterol.
DB00935
Methysergide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.
DB00968
Methysergide may increase the hypertensive and vasoconstricting activities of Methyldopa.
DB00983
Methysergide may increase the hypertensive and vasoconstricting activities of Formoterol.
DB01064
Methysergide may increase the hypertensive and vasoconstricting activities of Isoprenaline.
DB01102
Methysergide may increase the hypertensive and vasoconstricting activities of Arbutamine.
DB01274
Methysergide may increase the hypertensive and vasoconstricting activities of Arformoterol.
DB01288
Methysergide may increase the hypertensive and vasoconstricting activities of Fenoterol.
DB01291
Methysergide may increase the hypertensive and vasoconstricting activities of Pirbuterol.
DB01363
Methysergide may increase the hypertensive and vasoconstricting activities of Ephedra sinica root.
DB01364
Methysergide may increase the hypertensive and vasoconstricting activities of Ephedrine.
DB01365
Methysergide may increase the hypertensive and vasoconstricting activities of Mephentermine.
DB01366
Methysergide may increase the hypertensive and vasoconstricting activities of Procaterol.
DB01407
Methysergide may increase the hypertensive and vasoconstricting activities of Clenbuterol.
DB01408
Methysergide may increase the hypertensive and vasoconstricting activities of Bambuterol.
DB01472
Methysergide may increase the hypertensive and vasoconstricting activities of 4-Methoxyamphetamine.
DB01537
Methysergide may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine.
DB01577
Methysergide may increase the hypertensive and vasoconstricting activities of Metamfetamine.
DB01579
Methysergide may increase the hypertensive and vasoconstricting activities of Phendimetrazine.
DB04846
Methysergide may increase the hypertensive and vasoconstricting activities of Celiprolol.
DB05395
Methysergide may increase the hypertensive and vasoconstricting activities of Amibegron.
DB06190
Methysergide may increase the hypertensive and vasoconstricting activities of Solabegron.
DB06262
Methysergide may increase the hypertensive and vasoconstricting activities of Droxidopa.
DB06694
Methysergide may increase the hypertensive and vasoconstricting activities of Xylometazoline.
DB06706
Methysergide may increase the hypertensive and vasoconstricting activities of Isometheptene.
DB06707
Methysergide may increase the hypertensive and vasoconstricting activities of Levonordefrin.
DB06711
Methysergide may increase the hypertensive and vasoconstricting activities of Naphazoline.
DB06764
Methysergide may increase the hypertensive and vasoconstricting activities of Tetryzoline.
DB06814
Methysergide may increase the hypertensive and vasoconstricting activities of Protokylol.
DB08925
Methysergide may increase the hypertensive and vasoconstricting activities of Adrafinil.
DB08941
Methysergide may increase the hypertensive and vasoconstricting activities of Isoxsuprine.
DB08957
Methysergide may increase the hypertensive and vasoconstricting activities of Hexoprenaline.
DB08985
Methysergide may increase the hypertensive and vasoconstricting activities of Etilefrine.
DB09080
Methysergide may increase the hypertensive and vasoconstricting activities of Olodaterol.
DB09202
Methysergide may increase the hypertensive and vasoconstricting activities of Cirazoline.
DB09203
Methysergide may increase the hypertensive and vasoconstricting activities of Synephrine.
DB09242
Methysergide may increase the hypertensive and vasoconstricting activities of Moxonidine.
DB09273
Methysergide may increase the hypertensive and vasoconstricting activities of Doxofylline.
DB11124
Methysergide may increase the hypertensive and vasoconstricting activities of Racepinephrine.
DB11278
Methysergide may increase the hypertensive and vasoconstricting activities of DL-Methylephedrine.
DB11373
Methysergide may increase the hypertensive and vasoconstricting activities of Amitraz.
DB11428
Methysergide may increase the hypertensive and vasoconstricting activities of Medetomidine.
DB11477
Methysergide may increase the hypertensive and vasoconstricting activities of Xylazine.
DB11541
Methysergide may increase the hypertensive and vasoconstricting activities of Ractopamine.
DB11543
Methysergide may increase the hypertensive and vasoconstricting activities of Romifidine.
DB11556
Methysergide may increase the hypertensive and vasoconstricting activities of Detomidine.
DB11587
Methysergide may increase the hypertensive and vasoconstricting activities of Etafedrine.
DB11738
Methysergide may increase the hypertensive and vasoconstricting activities of Rilmenidine.
DB11785
Methysergide may increase the hypertensive and vasoconstricting activities of Anisodamine.
DB11871
Methysergide may increase the hypertensive and vasoconstricting activities of PF-00610355.
DB12080
Methysergide may increase the hypertensive and vasoconstricting activities of Ritobegron.
DB12100
Methysergide may increase the hypertensive and vasoconstricting activities of Abediterol.
DB12248
Methysergide may increase the hypertensive and vasoconstricting activities of Tulobuterol.
DB12313
Methysergide may increase the hypertensive and vasoconstricting activities of Dopexamine.
DB12526
Methysergide may increase the hypertensive and vasoconstricting activities of Batefenterol.
DB12779
Methysergide may increase the hypertensive and vasoconstricting activities of Higenamine.
DB12846
Methysergide may increase the hypertensive and vasoconstricting activities of Reproterol.
DB13251
Methysergide may increase the hypertensive and vasoconstricting activities of Octopamine.
DB13378
Methysergide may increase the hypertensive and vasoconstricting activities of Norfenefrine.
DB13398
Methysergide may increase the hypertensive and vasoconstricting activities of Oxyfedrine.
DB13559
Methysergide may increase the hypertensive and vasoconstricting activities of Rimiterol.
DB13624
Methysergide may increase the hypertensive and vasoconstricting activities of Methoxyphenamine.
DB13692
Methysergide may increase the hypertensive and vasoconstricting activities of Tretoquinol.
DB13777
Methysergide may increase the hypertensive and vasoconstricting activities of Prenalterol.
DB13781
Methysergide may increase the hypertensive and vasoconstricting activities of Xamoterol.
DB14752
Methysergide may increase the hypertensive and vasoconstricting activities of Racephedrine.
DB01018
Methysergide may increase the hypertensive and vasoconstricting activities of Guanfacine.
DB04861
Methysergide may increase the hypertensive and vasoconstricting activities of Nebivolol.
DB00865
Methysergide may increase the hypertensive and vasoconstricting activities of Benzphetamine.
DB01253
Methysergide may increase the hypertensive and vasoconstricting activities of Ergometrine.
DB00938
Methysergide may increase the hypertensive and vasoconstricting activities of Salmeterol.
DB01001
Methysergide may increase the hypertensive and vasoconstricting activities of Salbutamol.
DB05039
Methysergide may increase the hypertensive and vasoconstricting activities of Indacaterol.
DB06152
Methysergide may increase the hypertensive and vasoconstricting activities of Nylidrin.
DB08893
Methysergide may increase the hypertensive and vasoconstricting activities of Mirabegron.
DB09082
Methysergide may increase the hypertensive and vasoconstricting activities of Vilanterol.
DB13139
Methysergide may increase the hypertensive and vasoconstricting activities of Levosalbutamol.
DB01186
Methysergide may increase the hypertensive and vasoconstricting activities of Pergolide.
DB01200
Methysergide may increase the hypertensive and vasoconstricting activities of Bromocriptine.
DB00668
Methysergide may increase the hypertensive and vasoconstricting activities of Epinephrine.
DB14547
Methysergide may increase the hypertensive and vasoconstricting activities of Chloride ion.
DB00187
Esmolol may increase the vasoconstricting activities of Methysergide.
DB00195
Betaxolol may increase the vasoconstricting activities of Methysergide.
DB00335
Atenolol may increase the vasoconstricting activities of Methysergide.
DB00373
Timolol may increase the vasoconstricting activities of Methysergide.
DB00489
Sotalol may increase the vasoconstricting activities of Methysergide.
DB00598
Labetalol may increase the vasoconstricting activities of Methysergide.
DB00866
Alprenolol may increase the vasoconstricting activities of Methysergide.
DB00960
Pindolol may increase the vasoconstricting activities of Methysergide.
DB01193
Acebutolol may increase the vasoconstricting activities of Methysergide.
DB01203
Nadolol may increase the vasoconstricting activities of Methysergide.
DB01295
Bevantolol may increase the vasoconstricting activities of Methysergide.
DB01297
Practolol may increase the vasoconstricting activities of Methysergide.
DB01359
Penbutolol may increase the vasoconstricting activities of Methysergide.
DB01580
Oxprenolol may increase the vasoconstricting activities of Methysergide.
DB03322
Dexpropranolol may increase the vasoconstricting activities of Methysergide.
DB06726
Bufuralol may increase the vasoconstricting activities of Methysergide.
DB08807
Bopindolol may increase the vasoconstricting activities of Methysergide.
DB08808
Bupranolol may increase the vasoconstricting activities of Methysergide.
DB08952
Indenolol may increase the vasoconstricting activities of Methysergide.
DB09204
Arotinolol may increase the vasoconstricting activities of Methysergide.
DB09351
Levobetaxolol may increase the vasoconstricting activities of Methysergide.
DB11770
Talinolol may increase the vasoconstricting activities of Methysergide.
DB12752
Bucindolol may increase the vasoconstricting activities of Methysergide.
DB13443
Esatenolol may increase the vasoconstricting activities of Methysergide.
DB13508
Cloranolol may increase the vasoconstricting activities of Methysergide.
DB13530
Mepindolol may increase the vasoconstricting activities of Methysergide.
DB13757
Epanolol may increase the vasoconstricting activities of Methysergide.
DB13775
Tertatolol may increase the vasoconstricting activities of Methysergide.
DB00571
Methysergide may increase the vasoconstricting activities of Propranolol.
DB00612
Methysergide may increase the vasoconstricting activities of Bisoprolol.
DB01136
Methysergide may increase the vasoconstricting activities of Carvedilol.
DB01182
Methysergide may increase the vasoconstricting activities of Propafenone.
DB12212
Methysergide may increase the vasoconstricting activities of Landiolol.
DB00209
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Trospium.
DB00219
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.
DB00245
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
DB00332
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.
DB00340
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Metixene.
DB00354
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Buclizine.
DB00376
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
DB00383
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.
DB00387
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.
DB00392
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Profenamine.
DB00424
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
DB00462
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.
DB00505
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.
DB00517
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.
DB00572
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Atropine.
DB00670
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.
DB00725
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.
DB00767
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Benzquinamide.
DB00782
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
DB00804
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
DB00810
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Biperiden.
DB00940
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
DB00942
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.
DB00986
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
DB01148
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
DB01231
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.
DB01625
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.
DB04843
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.
DB06787
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.
DB08801
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.
DB08897
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
DB08997
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
DB09076
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium.
DB09300
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.
DB11235
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
DB11315
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
DB11855
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.
DB12086
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.
DB12554
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
DB13252
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.
DB13254
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
DB13351
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.
DB13369
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Benzilone.
DB13380
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Difemerine.
DB13413
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Phenglutarimide.
DB13448
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Mazaticol.
DB13468
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
DB13507
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Poldine.
DB13542
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Bevonium.
DB13581
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Rociverine.
DB13619
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.
DB13636
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Etanautine.
DB13666
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.
DB13678
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.
DB13695
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Penthienate.
DB13720
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.
DB13738
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Camylofin.
DB13759
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.
DB13769
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.
DB13844
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
DB13850
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Timepidium.
DB00835
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
DB00280
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
DB00420
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Promazine.
DB00907
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
DB01036
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
DB01224
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
DB01409
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Tiotropium.
DB01591
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
DB06702
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
DB09089
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.
DB09262
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.
DB12278
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Propiverine.
DB13500
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Otilonium.
DB00321
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
DB00458
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
DB01142
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DB00622
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.
DB00477
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
DB00496
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
DB01062
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
DB01151
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DB00363
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
DB09007
Methysergide may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.
DB01198
The risk or severity of adverse effects can be increased when Methysergide is combined with Zopiclone.
DB00745
The metabolism of Methysergide can be increased when combined with Modafinil.
DB00559
The metabolism of Bosentan can be increased when combined with Methysergide.
DB00307
The metabolism of Methysergide can be increased when combined with Bexarotene.
DB00607
The metabolism of Methysergide can be increased when combined with Nafcillin.
DB06414
The metabolism of Methysergide can be increased when combined with Etravirine.
DB06442
The metabolism of Methysergide can be increased when combined with Avasimibe.
DB14240
The metabolism of Methysergide can be increased when combined with Echinacea.
DB00312
The metabolism of Pentobarbital can be increased when combined with Methysergide.
DB00564
The metabolism of Carbamazepine can be increased when combined with Methysergide.
DB00794
The metabolism of Primidone can be increased when combined with Methysergide.
DB01174
The metabolism of Phenobarbital can be increased when combined with Methysergide.
DB01323
The metabolism of St. John's Wort can be increased when combined with Methysergide.
DB01234
The metabolism of Methysergide can be increased when combined with Dexamethasone.
DB00648
The metabolism of Methysergide can be increased when combined with Mitotane.
DB01045
The metabolism of Methysergide can be increased when combined with Rifampicin.
DB01220
The metabolism of Methysergide can be increased when combined with Rifaximin.
DB06595
The metabolism of Methysergide can be increased when combined with Midostaurin.
DB08899
The metabolism of Methysergide can be increased when combined with Enzalutamide.
DB09280
The metabolism of Methysergide can be increased when combined with Lumacaftor.
DB11753
The metabolism of Methysergide can be increased when combined with Rifamycin.
DB11901
The metabolism of Methysergide can be increased when combined with Apalutamide.
DB00270
The metabolism of Isradipine can be decreased when combined with Methysergide.
DB00343
The metabolism of Diltiazem can be decreased when combined with Methysergide.
DB06712
The metabolism of Nilvadipine can be decreased when combined with Methysergide.
DB00196
The metabolism of Methysergide can be decreased when combined with Fluconazole.
DB00227
The metabolism of Methysergide can be decreased when combined with Lovastatin.
DB00537
The metabolism of Methysergide can be decreased when combined with Ciprofloxacin.
DB00661
The metabolism of Methysergide can be decreased when combined with Verapamil.
DB00673
The metabolism of Methysergide can be decreased when combined with Aprepitant.
DB00951
The metabolism of Methysergide can be decreased when combined with Isoniazid.
DB01087
The metabolism of Methysergide can be decreased when combined with Primaquine.
DB01110
The metabolism of Methysergide can be decreased when combined with Miconazole.
DB01406
The metabolism of Methysergide can be decreased when combined with Danazol.
DB02703
The metabolism of Methysergide can be decreased when combined with Fusidic acid.
DB06290
The metabolism of Methysergide can be decreased when combined with Simeprevir.
DB06636
The metabolism of Methysergide can be decreased when combined with Isavuconazonium.
DB08882
The metabolism of Methysergide can be decreased when combined with Linagliptin.
DB09048
The metabolism of Methysergide can be decreased when combined with Netupitant.
DB09227
The metabolism of Methysergide can be decreased when combined with Barnidipine.
DB09231
The metabolism of Methysergide can be decreased when combined with Benidipine.
DB14019
The metabolism of Methysergide can be decreased when combined with Fosnetupitant.
DB11633
The metabolism of Methysergide can be decreased when combined with Isavuconazole.
DB15982
The metabolism of Methysergide can be decreased when combined with Berotralstat.
DB01149
The metabolism of Nefazodone can be decreased when combined with Methysergide.
DB00342
The metabolism of Terfenadine can be decreased when combined with Methysergide.
DB00625
The metabolism of Efavirenz can be decreased when combined with Methysergide.
DB00696
The metabolism of Ergotamine can be decreased when combined with Methysergide.
DB09118
The metabolism of Stiripentol can be decreased when combined with Methysergide.
DB00582
The metabolism of Methysergide can be decreased when combined with Voriconazole.
DB00705
The metabolism of Methysergide can be decreased when combined with Delavirdine.
DB00763
The metabolism of Methysergide can be decreased when combined with Methimazole.
DB00836
The metabolism of Methysergide can be decreased when combined with Loperamide.
DB00872
The metabolism of Methysergide can be decreased when combined with Conivaptan.
DB00932
The metabolism of Methysergide can be decreased when combined with Tipranavir.
DB01026
The metabolism of Methysergide can be decreased when combined with Ketoconazole.
DB01072
The metabolism of Methysergide can be decreased when combined with Atazanavir.
DB01167
The metabolism of Methysergide can be decreased when combined with Itraconazole.
DB01183
The metabolism of Methysergide can be decreased when combined with Naloxone.
DB01232
The metabolism of Methysergide can be decreased when combined with Saquinavir.
DB01264
The metabolism of Methysergide can be decreased when combined with Darunavir.
DB02520
The metabolism of Methysergide can be decreased when combined with Ditiocarb.
DB04868
The metabolism of Methysergide can be decreased when combined with Nilotinib.
DB05521
The metabolism of Methysergide can be decreased when combined with Telaprevir.
DB09101
The metabolism of Methysergide can be decreased when combined with Elvitegravir.
DB11730
The metabolism of Methysergide can be decreased when combined with Ribociclib.
DB11779
The metabolism of Methysergide can be decreased when combined with Danoprevir.
DB13179
The metabolism of Methysergide can be decreased when combined with Troleandomycin.
DB06448
The metabolism of Methysergide can be decreased when combined with Lonafarnib.
DB00042
The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methysergide.
DB00083
The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methysergide.
DB00150
The risk or severity of adverse effects can be increased when Tryptophan is combined with Methysergide.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Methysergide.
DB00182
The risk or severity of adverse effects can be increased when Amphetamine is combined with Methysergide.
DB00189
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methysergide.
DB00202
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methysergide.
DB00206
The risk or severity of adverse effects can be increased when Reserpine is combined with Methysergide.
DB00228
The risk or severity of adverse effects can be increased when Enflurane is combined with Methysergide.
DB00237
The risk or severity of adverse effects can be increased when Butabarbital is combined with Methysergide.
DB00283
The risk or severity of adverse effects can be increased when Methysergide is combined with Clemastine.
DB00289
The risk or severity of adverse effects can be increased when Methysergide is combined with Atomoxetine.
DB00306
The risk or severity of adverse effects can be increased when Methysergide is combined with Talbutal.
DB00323
The risk or severity of adverse effects can be increased when Methysergide is combined with Tolcapone.
DB00341
The risk or severity of adverse effects can be increased when Methysergide is combined with Cetirizine.
DB00344
The risk or severity of adverse effects can be increased when Methysergide is combined with Protriptyline.
DB00371
The risk or severity of adverse effects can be increased when Methysergide is combined with Meprobamate.
DB00372
The risk or severity of adverse effects can be increased when Methysergide is combined with Thiethylperazine.
DB00391
The risk or severity of adverse effects can be increased when Methysergide is combined with Sulpiride.
DB00405
The risk or severity of adverse effects can be increased when Methysergide is combined with Dexbrompheniramine.
DB00408
The risk or severity of adverse effects can be increased when Methysergide is combined with Loxapine.
DB00409
The risk or severity of adverse effects can be increased when Methysergide is combined with Remoxipride.
DB00416
The risk or severity of adverse effects can be increased when Methysergide is combined with Metocurine iodide.
DB00423
The risk or severity of adverse effects can be increased when Methysergide is combined with Methocarbamol.
DB00427
The risk or severity of adverse effects can be increased when Methysergide is combined with Triprolidine.
DB00434
The risk or severity of adverse effects can be increased when Methysergide is combined with Cyproheptadine.
DB00463
The risk or severity of adverse effects can be increased when Methysergide is combined with Metharbital.
DB00483
The risk or severity of adverse effects can be increased when Methysergide is combined with Gallamine triethiodide.
DB00494
The risk or severity of adverse effects can be increased when Methysergide is combined with Entacapone.
DB00508
The risk or severity of adverse effects can be increased when Methysergide is combined with Triflupromazine.
DB00532
The risk or severity of adverse effects can be increased when Methysergide is combined with Mephenytoin.
DB00543
The risk or severity of adverse effects can be increased when Methysergide is combined with Amoxapine.
DB00555
The risk or severity of adverse effects can be increased when Methysergide is combined with Lamotrigine.
DB00565
The risk or severity of adverse effects can be increased when Methysergide is combined with Cisatracurium.
DB00574
The risk or severity of adverse effects can be increased when Methysergide is combined with Fenfluramine.
DB00579
The risk or severity of adverse effects can be increased when Methysergide is combined with Mazindol.
DB00601
The risk or severity of adverse effects can be increased when Methysergide is combined with Linezolid.
DB00611
The risk or severity of adverse effects can be increased when Methysergide is combined with Butorphanol.
DB00614
The risk or severity of adverse effects can be increased when Methysergide is combined with Furazolidone.
DB00623
The risk or severity of adverse effects can be increased when Methysergide is combined with Fluphenazine.
DB00645
The risk or severity of adverse effects can be increased when Methysergide is combined with Dyclonine.
DB00652
The risk or severity of adverse effects can be increased when Methysergide is combined with Pentazocine.
DB00660
The risk or severity of adverse effects can be increased when Methysergide is combined with Metaxalone.
DB00662
The risk or severity of adverse effects can be increased when Methysergide is combined with Trimethobenzamide.
DB00679
The risk or severity of adverse effects can be increased when Methysergide is combined with Thioridazine.
DB00680
The risk or severity of adverse effects can be increased when Methysergide is combined with Moricizine.
DB00714
The risk or severity of adverse effects can be increased when Methysergide is combined with Apomorphine.
DB00721
The risk or severity of adverse effects can be increased when Methysergide is combined with Procaine.
DB00728
The risk or severity of adverse effects can be increased when Methysergide is combined with Rocuronium.
DB00732
The risk or severity of adverse effects can be increased when Methysergide is combined with Atracurium besylate.
DB00737
The risk or severity of adverse effects can be increased when Methysergide is combined with Meclizine.
DB00740
The risk or severity of adverse effects can be increased when Methysergide is combined with Riluzole.
DB00747
The risk or severity of adverse effects can be increased when Methysergide is combined with Scopolamine.
DB00753
The risk or severity of adverse effects can be increased when Methysergide is combined with Isoflurane.
DB00771
The risk or severity of adverse effects can be increased when Methysergide is combined with Clidinium.
DB00777
The risk or severity of adverse effects can be increased when Methysergide is combined with Propiomazine.
DB00801
The risk or severity of adverse effects can be increased when Methysergide is combined with Halazepam.
DB00805
The risk or severity of adverse effects can be increased when Methysergide is combined with Minaprine.
DB00831
The risk or severity of adverse effects can be increased when Methysergide is combined with Trifluoperazine.
DB00832
The risk or severity of adverse effects can be increased when Methysergide is combined with Phensuximide.
DB00837
The risk or severity of adverse effects can be increased when Methysergide is combined with Progabide.
DB00844
The risk or severity of adverse effects can be increased when Methysergide is combined with Nalbuphine.
DB00854
The risk or severity of adverse effects can be increased when Methysergide is combined with Levorphanol.
DB00875
The risk or severity of adverse effects can be increased when Methysergide is combined with Flupentixol.
DB00899
The risk or severity of adverse effects can be increased when Methysergide is combined with Remifentanil.
DB00933
The risk or severity of adverse effects can be increased when Methysergide is combined with Mesoridazine.
DB00934
The risk or severity of adverse effects can be increased when Methysergide is combined with Maprotiline.
DB00937
The risk or severity of adverse effects can be increased when Methysergide is combined with Diethylpropion.
DB00941
The risk or severity of adverse effects can be increased when Methysergide is combined with Hexafluronium.
DB00967
The risk or severity of adverse effects can be increased when Methysergide is combined with Desloratadine.
DB00985
The risk or severity of adverse effects can be increased when Methysergide is combined with Dimenhydrinate.
DB01063
The risk or severity of adverse effects can be increased when Methysergide is combined with Acetophenazine.
DB01065
The risk or severity of adverse effects can be increased when Methysergide is combined with Melatonin.
DB01069
The risk or severity of adverse effects can be increased when Methysergide is combined with Promethazine.
DB01075
The risk or severity of adverse effects can be increased when Methysergide is combined with Diphenhydramine.
DB01080
The risk or severity of adverse effects can be increased when Methysergide is combined with Vigabatrin.
DB01081
The risk or severity of adverse effects can be increased when Methysergide is combined with Diphenoxylate.
DB01107
The risk or severity of adverse effects can be increased when Methysergide is combined with Methyprylon.
DB01121
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenacemide.
DB01135
The risk or severity of adverse effects can be increased when Methysergide is combined with Doxacurium.
DB01168
The risk or severity of adverse effects can be increased when Methysergide is combined with Procarbazine.
DB01171
The risk or severity of adverse effects can be increased when Methysergide is combined with Moclobemide.
DB01176
The risk or severity of adverse effects can be increased when Methysergide is combined with Cyclizine.
DB01178
The risk or severity of adverse effects can be increased when Methysergide is combined with Chlormezanone.
DB01189
The risk or severity of adverse effects can be increased when Methysergide is combined with Desflurane.
DB01199
The risk or severity of adverse effects can be increased when Methysergide is combined with Tubocurarine.
DB01209
The risk or severity of adverse effects can be increased when Methysergide is combined with Dezocine.
DB01226
The risk or severity of adverse effects can be increased when Methysergide is combined with Mivacurium.
DB01235
The risk or severity of adverse effects can be increased when Methysergide is combined with Levodopa.
DB01239
The risk or severity of adverse effects can be increased when Methysergide is combined with Chlorprothixene.
DB01245
The risk or severity of adverse effects can be increased when Methysergide is combined with Decamethonium.
DB01247
The risk or severity of adverse effects can be increased when Methysergide is combined with Isocarboxazid.
DB01336
The risk or severity of adverse effects can be increased when Methysergide is combined with Metocurine.
DB01337
The risk or severity of adverse effects can be increased when Methysergide is combined with Pancuronium.
DB01338
The risk or severity of adverse effects can be increased when Methysergide is combined with Pipecuronium.
DB01339
The risk or severity of adverse effects can be increased when Methysergide is combined with Vecuronium.
DB01353
The risk or severity of adverse effects can be increased when Methysergide is combined with Butobarbital.
DB01354
The risk or severity of adverse effects can be increased when Methysergide is combined with Heptabarbital.
DB01356
The risk or severity of adverse effects can be increased when Methysergide is combined with Lithium cation.
DB01367
The risk or severity of adverse effects can be increased when Methysergide is combined with Rasagiline.
DB01433
The risk or severity of adverse effects can be increased when Methysergide is combined with Methadyl acetate.
DB01437
The risk or severity of adverse effects can be increased when Methysergide is combined with Glutethimide.
DB01440
The risk or severity of adverse effects can be increased when Methysergide is combined with gamma-Hydroxybutyric acid.
DB01442
The risk or severity of adverse effects can be increased when Methysergide is combined with MMDA.
DB01445
The risk or severity of adverse effects can be increased when Methysergide is combined with Bufotenine.
DB01450
The risk or severity of adverse effects can be increased when Methysergide is combined with Dihydroetorphine.
DB01452
The risk or severity of adverse effects can be increased when Methysergide is combined with Diamorphine.
DB01454
The risk or severity of adverse effects can be increased when Methysergide is combined with Midomafetamine.
DB01463
The risk or severity of adverse effects can be increased when Methysergide is combined with Fencamfamin.
DB01484
The risk or severity of adverse effects can be increased when Methysergide is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB01488
The risk or severity of adverse effects can be increased when Methysergide is combined with Dimethyltryptamine.
DB01489
The risk or severity of adverse effects can be increased when Methysergide is combined with Camazepam.
DB01495
The risk or severity of adverse effects can be increased when Methysergide is combined with Dichloralphenazone.
DB01497
The risk or severity of adverse effects can be increased when Methysergide is combined with Etorphine.
DB01501
The risk or severity of adverse effects can be increased when Methysergide is combined with Difenoxin.
DB01509
The risk or severity of adverse effects can be increased when Methysergide is combined with Tenamfetamine.
DB01511
The risk or severity of adverse effects can be increased when Methysergide is combined with Delorazepam.
DB01529
The risk or severity of adverse effects can be increased when Methysergide is combined with Dextromoramide.
DB01531
The risk or severity of adverse effects can be increased when Methysergide is combined with Desomorphine.
DB01534
The risk or severity of adverse effects can be increased when Methysergide is combined with Chlorhexadol.
DB01535
The risk or severity of adverse effects can be increased when Methysergide is combined with Carfentanil.
DB01545
The risk or severity of adverse effects can be increased when Methysergide is combined with Ethyl loflazepate.
DB01547
The risk or severity of adverse effects can be increased when Methysergide is combined with Drotebanol.
DB01553
The risk or severity of adverse effects can be increased when Methysergide is combined with Cloxazolam.
DB01555
The risk or severity of adverse effects can be increased when Methysergide is combined with Alphacetylmethadol.
DB01560
The risk or severity of adverse effects can be increased when Methysergide is combined with Cathinone.
DB01563
The risk or severity of adverse effects can be increased when Methysergide is combined with Chloral hydrate.
DB01565
The risk or severity of adverse effects can be increased when Methysergide is combined with Dihydromorphine.
DB01567
The risk or severity of adverse effects can be increased when Methysergide is combined with Fludiazepam.
DB01594
The risk or severity of adverse effects can be increased when Methysergide is combined with Cinolazepam.
DB01608
The risk or severity of adverse effects can be increased when Methysergide is combined with Periciazine.
DB01614
The risk or severity of adverse effects can be increased when Methysergide is combined with Acepromazine.
DB01615
The risk or severity of adverse effects can be increased when Methysergide is combined with Aceprometazine.
DB01616
The risk or severity of adverse effects can be increased when Methysergide is combined with Alverine.
DB01618
The risk or severity of adverse effects can be increased when Methysergide is combined with Molindone.
DB01622
The risk or severity of adverse effects can be increased when Methysergide is combined with Thioproperazine.
DB01623
The risk or severity of adverse effects can be increased when Methysergide is combined with Thiothixene.
DB01626
The risk or severity of adverse effects can be increased when Methysergide is combined with Pargyline.
DB01954
The risk or severity of adverse effects can be increased when Methysergide is combined with Rolipram.
DB02207
The risk or severity of adverse effects can be increased when Methysergide is combined with 7-Nitroindazole.
DB02234
The risk or severity of adverse effects can be increased when Methysergide is combined with S-Ethylisothiourea.
DB02852
The risk or severity of adverse effects can be increased when Methysergide is combined with Domoic Acid.
DB02959
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxitriptan.
DB03575
The risk or severity of adverse effects can be increased when Methysergide is combined with Phencyclidine.
DB04017
The risk or severity of adverse effects can be increased when Methysergide is combined with Clorgiline.
DB04165
The risk or severity of adverse effects can be increased when Methysergide is combined with Valpromide.
DB04325
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenethylamine.
DB04599
The risk or severity of adverse effects can be increased when Methysergide is combined with Aniracetam.
DB04818
The risk or severity of adverse effects can be increased when Methysergide is combined with Iproniazid.
DB04819
The risk or severity of adverse effects can be increased when Methysergide is combined with Methapyrilene.
DB04820
The risk or severity of adverse effects can be increased when Methysergide is combined with Nialamide.
DB04821
The risk or severity of adverse effects can be increased when Methysergide is combined with Nomifensine.
DB04827
The risk or severity of adverse effects can be increased when Methysergide is combined with Urethane.
DB04834
The risk or severity of adverse effects can be increased when Methysergide is combined with Rapacuronium.
DB04836
The risk or severity of adverse effects can be increased when Methysergide is combined with Amineptine.
DB04872
The risk or severity of adverse effects can be increased when Methysergide is combined with Osanetant.
DB04885
The risk or severity of adverse effects can be increased when Methysergide is combined with Cilansetron.
DB04888
The risk or severity of adverse effects can be increased when Methysergide is combined with Bifeprunox.
DB04903
The risk or severity of adverse effects can be increased when Methysergide is combined with Pagoclone.
DB04917
The risk or severity of adverse effects can be increased when Methysergide is combined with Renzapride.
DB04953
The risk or severity of adverse effects can be increased when Methysergide is combined with Ezogabine.
DB05227
The risk or severity of adverse effects can be increased when Methysergide is combined with APD791.
DB05232
The risk or severity of adverse effects can be increased when Methysergide is combined with Tetrodotoxin.
DB05246
The risk or severity of adverse effects can be increased when Methysergide is combined with Methsuximide.
DB05316
The risk or severity of adverse effects can be increased when Methysergide is combined with Pimavanserin.
DB05542
The risk or severity of adverse effects can be increased when Methysergide is combined with Naronapride.
DB05607
The risk or severity of adverse effects can be increased when Methysergide is combined with PRX-08066.
DB05687
The risk or severity of adverse effects can be increased when Methysergide is combined with BL-1020.
DB05710
The risk or severity of adverse effects can be increased when Methysergide is combined with Gantacurium.
DB06077
The risk or severity of adverse effects can be increased when Methysergide is combined with Lumateperone.
DB06109
The risk or severity of adverse effects can be increased when Methysergide is combined with YKP-1358.
DB06153
The risk or severity of adverse effects can be increased when Methysergide is combined with Pizotifen.
DB06264
The risk or severity of adverse effects can be increased when Methysergide is combined with Tolperisone.
DB06288
The risk or severity of adverse effects can be increased when Methysergide is combined with Amisulpride.
DB06512
The risk or severity of adverse effects can be increased when Methysergide is combined with Deramciclane.
DB06527
The risk or severity of adverse effects can be increased when Methysergide is combined with Tramiprosate.
DB06529
The risk or severity of adverse effects can be increased when Methysergide is combined with Ocinaplon.
DB06554
The risk or severity of adverse effects can be increased when Methysergide is combined with Gaboxadol.
DB06579
The risk or severity of adverse effects can be increased when Methysergide is combined with Adipiplon.
DB06582
The risk or severity of adverse effects can be increased when Methysergide is combined with Dextofisopam.
DB06594
The risk or severity of adverse effects can be increased when Methysergide is combined with Agomelatine.
DB06660
The risk or severity of adverse effects can be increased when Methysergide is combined with Saredutant.
DB06678
The risk or severity of adverse effects can be increased when Methysergide is combined with Esmirtazapine.
DB06690
The risk or severity of adverse effects can be increased when Methysergide is combined with Nitrous oxide.
DB06691
The risk or severity of adverse effects can be increased when Methysergide is combined with Mepyramine.
DB06701
The risk or severity of adverse effects can be increased when Methysergide is combined with Dexmethylphenidate.
DB06716
The risk or severity of adverse effects can be increased when Methysergide is combined with Fospropofol.
DB06753
The risk or severity of adverse effects can be increased when Methysergide is combined with Triclofos.
DB06770
The risk or severity of adverse effects can be increased when Methysergide is combined with Benzyl alcohol.
DB06797
The risk or severity of adverse effects can be increased when Methysergide is combined with Mebutamate.
DB08059
The risk or severity of adverse effects can be increased when Methysergide is combined with Wortmannin.
DB08329
The risk or severity of adverse effects can be increased when Methysergide is combined with Sulthiame.
DB08550
The risk or severity of adverse effects can be increased when Methysergide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
DB08839
The risk or severity of adverse effects can be increased when Methysergide is combined with Serotonin.
DB08861
The risk or severity of adverse effects can be increased when Methysergide is combined with DPDPE.
DB08872
The risk or severity of adverse effects can be increased when Methysergide is combined with Gabapentin enacarbil.
DB08892
The risk or severity of adverse effects can be increased when Methysergide is combined with Arbaclofen Placarbil.
DB08927
The risk or severity of adverse effects can be increased when Methysergide is combined with Amperozide.
DB08954
The risk or severity of adverse effects can be increased when Methysergide is combined with Ifenprodil.
DB08960
The risk or severity of adverse effects can be increased when Methysergide is combined with Hexamethonium.
DB08986
The risk or severity of adverse effects can be increased when Methysergide is combined with Etifoxine.
DB08996
The risk or severity of adverse effects can be increased when Methysergide is combined with Dimetacrine.
DB09000
The risk or severity of adverse effects can be increased when Methysergide is combined with Cyamemazine.
DB09011
The risk or severity of adverse effects can be increased when Methysergide is combined with Beclamide.
DB09014
The risk or severity of adverse effects can be increased when Methysergide is combined with Captodiame.
DB09016
The risk or severity of adverse effects can be increased when Methysergide is combined with Butriptyline.
DB09021
The risk or severity of adverse effects can be increased when Methysergide is combined with Benzoctamine.
DB09023
The risk or severity of adverse effects can be increased when Methysergide is combined with Benactyzine.
DB09167
The risk or severity of adverse effects can be increased when Methysergide is combined with Dosulepin.
DB09174
The risk or severity of adverse effects can be increased when Methysergide is combined with Lofentanil.
DB09184
The risk or severity of adverse effects can be increased when Methysergide is combined with Edivoxetine.
DB09185
The risk or severity of adverse effects can be increased when Methysergide is combined with Viloxazine.
DB09186
The risk or severity of adverse effects can be increased when Methysergide is combined with Nisoxetine.
DB09187
The risk or severity of adverse effects can be increased when Methysergide is combined with Lortalamine.
DB09190
The risk or severity of adverse effects can be increased when Methysergide is combined with Talopram.
DB09194
The risk or severity of adverse effects can be increased when Methysergide is combined with Etoperidone.
DB09224
The risk or severity of adverse effects can be increased when Methysergide is combined with Melperone.
DB09226
The risk or severity of adverse effects can be increased when Methysergide is combined with Brilaroxazine.
DB09243
The risk or severity of adverse effects can be increased when Methysergide is combined with Hydracarbazine.
DB09244
The risk or severity of adverse effects can be increased when Methysergide is combined with Pirlindole.
DB09245
The risk or severity of adverse effects can be increased when Methysergide is combined with Toloxatone.
DB09246
The risk or severity of adverse effects can be increased when Methysergide is combined with Benmoxin.
DB09247
The risk or severity of adverse effects can be increased when Methysergide is combined with Iproclozide.
DB09248
The risk or severity of adverse effects can be increased when Methysergide is combined with Mebanazine.
DB09249
The risk or severity of adverse effects can be increased when Methysergide is combined with Octamoxin.
DB09250
The risk or severity of adverse effects can be increased when Methysergide is combined with Pheniprazine.
DB09251
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenoxypropazine.
DB09252
The risk or severity of adverse effects can be increased when Methysergide is combined with Pivhydrazine.
DB09253
The risk or severity of adverse effects can be increased when Methysergide is combined with Safrazine.
DB09254
The risk or severity of adverse effects can be increased when Methysergide is combined with Caroxazone.
DB09286
The risk or severity of adverse effects can be increased when Methysergide is combined with Pipamperone.
DB09290
The risk or severity of adverse effects can be increased when Methysergide is combined with Ramosetron.
DB09307
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxaprotiline.
DB11156
The risk or severity of adverse effects can be increased when Methysergide is combined with Pyrantel.
DB11371
The risk or severity of adverse effects can be increased when Methysergide is combined with Alfaxalone.
DB11376
The risk or severity of adverse effects can be increased when Methysergide is combined with Azaperone.
DB11540
The risk or severity of adverse effects can be increased when Methysergide is combined with Propiopromazine.
DB11549
The risk or severity of adverse effects can be increased when Methysergide is combined with Tiletamine.
DB11552
The risk or severity of adverse effects can be increased when Methysergide is combined with Tricaine.
DB11555
The risk or severity of adverse effects can be increased when Methysergide is combined with Zolazepam.
DB11582
The risk or severity of adverse effects can be increased when Methysergide is combined with Thiocolchicoside.
DB11609
The risk or severity of adverse effects can be increased when Methysergide is combined with Normethadone.
DB11664
The risk or severity of adverse effects can be increased when Methysergide is combined with Psilocybin.
DB11675
The risk or severity of adverse effects can be increased when Methysergide is combined with Mosapride.
DB11686
The risk or severity of adverse effects can be increased when Methysergide is combined with Iferanserin.
DB11699
The risk or severity of adverse effects can be increased when Methysergide is combined with Tropisetron.
DB11859
The risk or severity of adverse effects can be increased when Methysergide is combined with Brexanolone.
DB11868
The risk or severity of adverse effects can be increased when Methysergide is combined with Etiracetam.
DB11889
The risk or severity of adverse effects can be increased when Methysergide is combined with Lanicemine.
DB11957
The risk or severity of adverse effects can be increased when Methysergide is combined with Idalopirdine.
DB12071
The risk or severity of adverse effects can be increased when Methysergide is combined with Vabicaserin.
DB12105
The risk or severity of adverse effects can be increased when Methysergide is combined with Imagabalin.
DB12110
The risk or severity of adverse effects can be increased when Methysergide is combined with m-Chlorophenylpiperazine.
DB12111
The risk or severity of adverse effects can be increased when Methysergide is combined with MK-212.
DB12163
The risk or severity of adverse effects can be increased when Methysergide is combined with Sarpogrelate.
DB12177
The risk or severity of adverse effects can be increased when Methysergide is combined with Eplivanserin.
DB12184
The risk or severity of adverse effects can be increased when Methysergide is combined with Gepirone.
DB12229
The risk or severity of adverse effects can be increased when Methysergide is combined with Cerlapirdine.
DB12273
The risk or severity of adverse effects can be increased when Methysergide is combined with Ecopipam.
DB12308
The risk or severity of adverse effects can be increased when Methysergide is combined with Eltanolone.
DB12327
The risk or severity of adverse effects can be increased when Methysergide is combined with Salvinorin A.
DB12338
The risk or severity of adverse effects can be increased when Methysergide is combined with Carisbamate.
DB12395
The risk or severity of adverse effects can be increased when Methysergide is combined with Esreboxetine.
DB12401
The risk or severity of adverse effects can be increased when Methysergide is combined with Bromperidol.
DB12427
The risk or severity of adverse effects can be increased when Methysergide is combined with Orvepitant.
DB12465
The risk or severity of adverse effects can be increased when Methysergide is combined with Ketanserin.
DB12492
The risk or severity of adverse effects can be increased when Methysergide is combined with Piritramide.
DB12518
The risk or severity of adverse effects can be increased when Methysergide is combined with Raclopride.
DB12576
The risk or severity of adverse effects can be increased when Methysergide is combined with AZD-3043.
DB12590
The risk or severity of adverse effects can be increased when Methysergide is combined with Indiplon.
DB12661
The risk or severity of adverse effects can be increased when Methysergide is combined with Urapidil.
DB12710
The risk or severity of adverse effects can be increased when Methysergide is combined with Perazine.
DB12725
The risk or severity of adverse effects can be increased when Methysergide is combined with TD-8954.
DB12833
The risk or severity of adverse effects can be increased when Methysergide is combined with Tandospirone.
DB12867
The risk or severity of adverse effects can be increased when Methysergide is combined with Benperidol.
DB12883
The risk or severity of adverse effects can be increased when Methysergide is combined with Eltoprazine.
DB12930
The risk or severity of adverse effects can be increased when Methysergide is combined with Opipramol.
DB12951
The risk or severity of adverse effects can be increased when Methysergide is combined with Pivagabine.
DB12958
The risk or severity of adverse effects can be increased when Methysergide is combined with Prothipendyl.
DB12989
The risk or severity of adverse effects can be increased when Methysergide is combined with Neosaxitoxin.
DB13014
The risk or severity of adverse effects can be increased when Methysergide is combined with Hypericin.
DB13025
The risk or severity of adverse effects can be increased when Methysergide is combined with Tiapride.
DB13082
The risk or severity of adverse effects can be increased when Methysergide is combined with Nefiracetam.
DB13099
The risk or severity of adverse effects can be increased when Methysergide is combined with Valnoctamide.
DB13114
The risk or severity of adverse effects can be increased when Methysergide is combined with Amitriptylinoxide.
DB13160
The risk or severity of adverse effects can be increased when Methysergide is combined with Alphaprodine.
DB13213
The risk or severity of adverse effects can be increased when Methysergide is combined with Butaperazine.
DB13219
The risk or severity of adverse effects can be increased when Methysergide is combined with Medifoxamine.
DB13221
The risk or severity of adverse effects can be increased when Methysergide is combined with Apronalide.
DB13225
The risk or severity of adverse effects can be increased when Methysergide is combined with Dibenzepin.
DB13234
The risk or severity of adverse effects can be increased when Methysergide is combined with Propanidid.
DB13246
The risk or severity of adverse effects can be increased when Methysergide is combined with Quinupramine.
DB13253
The risk or severity of adverse effects can be increased when Methysergide is combined with Proxibarbal.
DB13256
The risk or severity of adverse effects can be increased when Methysergide is combined with Clothiapine.
DB13273
The risk or severity of adverse effects can be increased when Methysergide is combined with Sultopride.
DB13295
The risk or severity of adverse effects can be increased when Methysergide is combined with Atracurium.
DB13303
The risk or severity of adverse effects can be increased when Methysergide is combined with Febarbamate.
DB13323
The risk or severity of adverse effects can be increased when Methysergide is combined with Trichloroethylene.
DB13324
The risk or severity of adverse effects can be increased when Methysergide is combined with Tetrazepam.
DB13331
The risk or severity of adverse effects can be increased when Methysergide is combined with Pyrithyldione.
DB13335
The risk or severity of adverse effects can be increased when Methysergide is combined with Pinazepam.
DB13352
The risk or severity of adverse effects can be increased when Methysergide is combined with Deanol.
DB13354
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenprobamate.
DB13357
The risk or severity of adverse effects can be increased when Methysergide is combined with Styramate.
DB13362
The risk or severity of adverse effects can be increased when Methysergide is combined with Pheneturide.
DB13370
The risk or severity of adverse effects can be increased when Methysergide is combined with Bromisoval.
DB13377
The risk or severity of adverse effects can be increased when Methysergide is combined with Vinbarbital.
DB13382
The risk or severity of adverse effects can be increased when Methysergide is combined with Chlorproethazine.
DB13384
The risk or severity of adverse effects can be increased when Methysergide is combined with Melitracen.
DB13396
The risk or severity of adverse effects can be increased when Methysergide is combined with Neocitrullamon.
DB13402
The risk or severity of adverse effects can be increased when Methysergide is combined with Acetylglycinamide chloral hydrate.
DB13403
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxypertine.
DB13411
The risk or severity of adverse effects can be increased when Methysergide is combined with Lofepramine.
DB13414
The risk or severity of adverse effects can be increased when Methysergide is combined with Fenyramidol.
DB13420
The risk or severity of adverse effects can be increased when Methysergide is combined with Thiazinam.
DB13437
The risk or severity of adverse effects can be increased when Methysergide is combined with Medazepam.
DB13454
The risk or severity of adverse effects can be increased when Methysergide is combined with Nicomorphine.
DB13455
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenibut.
DB13457
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxaflozane.
DB13478
The risk or severity of adverse effects can be increased when Methysergide is combined with Meptazinol.
DB13496
The risk or severity of adverse effects can be increased when Methysergide is combined with Iprindole.
DB13505
The risk or severity of adverse effects can be increased when Methysergide is combined with Emepronium.
DB13520
The risk or severity of adverse effects can be increased when Methysergide is combined with Metergoline.
DB13522
The risk or severity of adverse effects can be increased when Methysergide is combined with Mebicar.
DB13523
The risk or severity of adverse effects can be increased when Methysergide is combined with Veralipride.
DB13534
The risk or severity of adverse effects can be increased when Methysergide is combined with Gedocarnil.
DB13541
The risk or severity of adverse effects can be increased when Methysergide is combined with Iprazochrome.
DB13550
The risk or severity of adverse effects can be increased when Methysergide is combined with Bifemelane.
DB13552
The risk or severity of adverse effects can be increased when Methysergide is combined with Trifluperidol.
DB13554
The risk or severity of adverse effects can be increased when Methysergide is combined with Moperone.
DB13557
The risk or severity of adverse effects can be increased when Methysergide is combined with Thiopropazate.
DB13572
The risk or severity of adverse effects can be increased when Methysergide is combined with Emylcamate.
DB13577
The risk or severity of adverse effects can be increased when Methysergide is combined with Allobarbital.
DB13584
The risk or severity of adverse effects can be increased when Methysergide is combined with Gallamine.
DB13588
The risk or severity of adverse effects can be increased when Methysergide is combined with Naftidrofuryl.
DB13598
The risk or severity of adverse effects can be increased when Methysergide is combined with Diethyl ether.
DB13601
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxiracetam.
DB13605
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenoperidine.
DB13606
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenazocine.
DB13623
The risk or severity of adverse effects can be increased when Methysergide is combined with Fabomotizole.
DB13642
The risk or severity of adverse effects can be increased when Methysergide is combined with Pridinol.
DB13643
The risk or severity of adverse effects can be increased when Methysergide is combined with Loprazolam.
DB13648
The risk or severity of adverse effects can be increased when Methysergide is combined with Alcuronium.
DB13662
The risk or severity of adverse effects can be increased when Methysergide is combined with Hexapropymate.
DB13665
The risk or severity of adverse effects can be increased when Methysergide is combined with Fluanisone.
DB13676
The risk or severity of adverse effects can be increased when Methysergide is combined with Mosapramine.
DB13687
The risk or severity of adverse effects can be increased when Methysergide is combined with Niaprazine.
DB13690
The risk or severity of adverse effects can be increased when Methysergide is combined with Vinyl ether.
DB13733
The risk or severity of adverse effects can be increased when Methysergide is combined with Methylpentynol.
DB13737
The risk or severity of adverse effects can be increased when Methysergide is combined with Cyclobarbital.
DB13745
The risk or severity of adverse effects can be increased when Methysergide is combined with Fazadinium bromide.
DB13754
The risk or severity of adverse effects can be increased when Methysergide is combined with Mephenoxalone.
DB13770
The risk or severity of adverse effects can be increased when Methysergide is combined with Vinylbital.
DB13782
The risk or severity of adverse effects can be increased when Methysergide is combined with Imipramine oxide.
DB13784
The risk or severity of adverse effects can be increased when Methysergide is combined with Dixyrazine.
DB13787
The risk or severity of adverse effects can be increased when Methysergide is combined with Tilidine.
DB13799
The risk or severity of adverse effects can be increased when Methysergide is combined with Ethadione.
DB13805
The risk or severity of adverse effects can be increased when Methysergide is combined with Reposal.
DB13817
The risk or severity of adverse effects can be increased when Methysergide is combined with Carbromal.
DB13837
The risk or severity of adverse effects can be increased when Methysergide is combined with Doxefazepam.
DB13841
The risk or severity of adverse effects can be increased when Methysergide is combined with Clopenthixol.
DB13872
The risk or severity of adverse effects can be increased when Methysergide is combined with Lormetazepam.
DB13875
The risk or severity of adverse effects can be increased when Methysergide is combined with Harmaline.
DB13876
The risk or severity of adverse effects can be increased when Methysergide is combined with Brofaromine.
DB13940
The risk or severity of adverse effects can be increased when Methysergide is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB13948
The risk or severity of adverse effects can be increased when Methysergide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DB13984
The risk or severity of adverse effects can be increased when Methysergide is combined with Cyclopropane.
DB13993
The risk or severity of adverse effects can be increased when Methysergide is combined with MRK-409.
DB14028
The risk or severity of adverse effects can be increased when Methysergide is combined with Nordazepam.
DB14050
The risk or severity of adverse effects can be increased when Methysergide is combined with Cannabidivarin.
DB14509
The risk or severity of adverse effects can be increased when Methysergide is combined with Lithium carbonate.
DB14651
The risk or severity of adverse effects can be increased when Methysergide is combined with Perphenazine enanthate.
DB14672
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxazepam acetate.
DB14715
The risk or severity of adverse effects can be increased when Methysergide is combined with Cinazepam.
DB14718
The risk or severity of adverse effects can be increased when Methysergide is combined with Pyrazolam.
DB14719
The risk or severity of adverse effects can be increased when Methysergide is combined with Bentazepam.
DB15203
The risk or severity of adverse effects can be increased when Methysergide is combined with JNJ-26489112.
DB15360
The risk or severity of adverse effects can be increased when Methysergide is combined with Carfentanil, C-11.
DB00334
The risk or severity of adverse effects can be increased when Olanzapine is combined with Methysergide.
DB01104
The risk or severity of adverse effects can be increased when Sertraline is combined with Methysergide.
DB01202
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Methysergide.
DB00231
The risk or severity of adverse effects can be increased when Temazepam is combined with Methysergide.
DB00327
The risk or severity of adverse effects can be increased when Methysergide is combined with Hydromorphone.
DB00475
The risk or severity of adverse effects can be increased when Methysergide is combined with Chlordiazepoxide.
DB00726
The risk or severity of adverse effects can be increased when Methysergide is combined with Trimipramine.
DB00748
The risk or severity of adverse effects can be increased when Methysergide is combined with Carbinoxamine.
DB00842
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxazepam.
DB00850
The risk or severity of adverse effects can be increased when Methysergide is combined with Perphenazine.
DB01156
The risk or severity of adverse effects can be increased when Methysergide is combined with Bupropion.
DB01219
The risk or severity of adverse effects can be increased when Methysergide is combined with Dantrolene.
DB01246
The risk or severity of adverse effects can be increased when Methysergide is combined with Alimemazine.
DB01558
The risk or severity of adverse effects can be increased when Methysergide is combined with Bromazepam.
DB01355
The risk or severity of adverse effects can be increased when Methysergide is combined with Hexobarbital.
DB00996
The risk or severity of adverse effects can be increased when Methysergide is combined with Gabapentin.
DB12093
The risk or severity of adverse effects can be increased when Methysergide is combined with Tetrahydropalmatine.
DB00234
The risk or severity of adverse effects can be increased when Reboxetine is combined with Methysergide.
DB00285
The risk or severity of adverse effects can be increased when Methysergide is combined with Venlafaxine.
DB00295
The risk or severity of adverse effects can be increased when Methysergide is combined with Morphine.
DB00318
The risk or severity of adverse effects can be increased when Methysergide is combined with Codeine.
DB00347
The risk or severity of adverse effects can be increased when Methysergide is combined with Trimethadione.
DB00356
The risk or severity of adverse effects can be increased when Methysergide is combined with Chlorzoxazone.
DB00377
The risk or severity of adverse effects can be increased when Methysergide is combined with Palonosetron.
DB00497
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxycodone.
DB00514
The risk or severity of adverse effects can be increased when Methysergide is combined with Dextromethorphan.
DB00546
The risk or severity of adverse effects can be increased when Methysergide is combined with Adinazolam.
DB00617
The risk or severity of adverse effects can be increased when Methysergide is combined with Paramethadione.
DB00628
The risk or severity of adverse effects can be increased when Methysergide is combined with Clorazepic acid.
DB00690
The risk or severity of adverse effects can be increased when Methysergide is combined with Flurazepam.
DB00708
The risk or severity of adverse effects can be increased when Methysergide is combined with Sufentanil.
DB00734
The risk or severity of adverse effects can be increased when Methysergide is combined with Risperidone.
DB00757
The risk or severity of adverse effects can be increased when Methysergide is combined with Dolasetron.
DB00843
The risk or severity of adverse effects can be increased when Methysergide is combined with Donepezil.
DB00889
The risk or severity of adverse effects can be increased when Methysergide is combined with Granisetron.
DB00904
The risk or severity of adverse effects can be increased when Methysergide is combined with Ondansetron.
DB00906
The risk or severity of adverse effects can be increased when Methysergide is combined with Tiagabine.
DB00909
The risk or severity of adverse effects can be increased when Methysergide is combined with Zonisamide.
DB00962
The risk or severity of adverse effects can be increased when Methysergide is combined with Zaleplon.
DB00969
The risk or severity of adverse effects can be increased when Methysergide is combined with Alosetron.
DB00980
The risk or severity of adverse effects can be increased when Methysergide is combined with Ramelteon.
DB01028
The risk or severity of adverse effects can be increased when Methysergide is combined with Methoxyflurane.
DB01037
The risk or severity of adverse effects can be increased when Methysergide is combined with Selegiline.
DB01049
The risk or severity of adverse effects can be increased when Methysergide is combined with Ergoloid mesylate.
DB01068
The risk or severity of adverse effects can be increased when Methysergide is combined with Clonazepam.
DB01114
The risk or severity of adverse effects can be increased when Methysergide is combined with Chlorpheniramine.
DB01159
The risk or severity of adverse effects can be increased when Methysergide is combined with Halothane.
DB01192
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxymorphone.
DB01215
The risk or severity of adverse effects can be increased when Methysergide is combined with Estazolam.
DB01236
The risk or severity of adverse effects can be increased when Methysergide is combined with Sevoflurane.
DB01267
The risk or severity of adverse effects can be increased when Methysergide is combined with Paliperidone.
DB01392
The risk or severity of adverse effects can be increased when Methysergide is combined with Yohimbine.
DB01466
The risk or severity of adverse effects can be increased when Methysergide is combined with Ethylmorphine.
DB01544
The risk or severity of adverse effects can be increased when Methysergide is combined with Flunitrazepam.
DB01551
The risk or severity of adverse effects can be increased when Methysergide is combined with Dihydrocodeine.
DB01559
The risk or severity of adverse effects can be increased when Methysergide is combined with Clotiazepam.
DB01588
The risk or severity of adverse effects can be increased when Methysergide is combined with Prazepam.
DB01589
The risk or severity of adverse effects can be increased when Methysergide is combined with Quazepam.
DB01595
The risk or severity of adverse effects can be increased when Methysergide is combined with Nitrazepam.
DB01621
The risk or severity of adverse effects can be increased when Methysergide is combined with Pipotiazine.
DB04829
The risk or severity of adverse effects can be increased when Methysergide is combined with Lysergic acid diethylamide.
DB04833
The risk or severity of adverse effects can be increased when Methysergide is combined with Methaqualone.
DB04841
The risk or severity of adverse effects can be increased when Methysergide is combined with Flunarizine.
DB04842
The risk or severity of adverse effects can be increased when Methysergide is combined with Fluspirilene.
DB04946
The risk or severity of adverse effects can be increased when Methysergide is combined with Iloperidone.
DB05541
The risk or severity of adverse effects can be increased when Methysergide is combined with Brivaracetam.
DB06144
The risk or severity of adverse effects can be increased when Methysergide is combined with Sertindole.
DB06148
The risk or severity of adverse effects can be increased when Methysergide is combined with Mianserin.
DB06216
The risk or severity of adverse effects can be increased when Methysergide is combined with Asenapine.
DB06282
The risk or severity of adverse effects can be increased when Methysergide is combined with Levocetirizine.
DB06283
The risk or severity of adverse effects can be increased when Methysergide is combined with Ziconotide.
DB06446
The risk or severity of adverse effects can be increased when Methysergide is combined with Dotarizine.
DB06470
The risk or severity of adverse effects can be increased when Methysergide is combined with Clomethiazole.
DB06654
The risk or severity of adverse effects can be increased when Methysergide is combined with Safinamide.
DB06738
The risk or severity of adverse effects can be increased when Methysergide is combined with Ketobemidone.
DB08922
The risk or severity of adverse effects can be increased when Methysergide is combined with Perospirone.
DB08992
The risk or severity of adverse effects can be increased when Methysergide is combined with Eperisone.
DB09017
The risk or severity of adverse effects can be increased when Methysergide is combined with Brotizolam.
DB09166
The risk or severity of adverse effects can be increased when Methysergide is combined with Etizolam.
DB09223
The risk or severity of adverse effects can be increased when Methysergide is combined with Blonanserin.
DB09225
The risk or severity of adverse effects can be increased when Methysergide is combined with Zotepine.
DB11130
The risk or severity of adverse effects can be increased when Methysergide is combined with Opium.
DB12131
The risk or severity of adverse effects can be increased when Methysergide is combined with Vinpocetine.
DB12537
The risk or severity of adverse effects can be increased when Methysergide is combined with Benzodiazepine.
DB13791
The risk or severity of adverse effects can be increased when Methysergide is combined with Penfluridol.
DB14185
The risk or severity of adverse effects can be increased when Methysergide is combined with Aripiprazole lauroxil.
DB11951
The risk or severity of adverse effects can be increased when Methysergide is combined with Lemborexant.
DB00241
The risk or severity of adverse effects can be increased when Butalbital is combined with Methysergide.
DB00273
The risk or severity of adverse effects can be increased when Methysergide is combined with Topiramate.
DB00313
The risk or severity of adverse effects can be increased when Methysergide is combined with Valproic acid.
DB00349
The risk or severity of adverse effects can be increased when Methysergide is combined with Clobazam.
DB00404
The risk or severity of adverse effects can be increased when Methysergide is combined with Alprazolam.
DB00418
The risk or severity of adverse effects can be increased when Methysergide is combined with Secobarbital.
DB00454
The risk or severity of adverse effects can be increased when Methysergide is combined with Meperidine.
DB00468
The risk or severity of adverse effects can be increased when Methysergide is combined with Quinine.
DB00474
The risk or severity of adverse effects can be increased when Methysergide is combined with Methohexital.
DB00588
The risk or severity of adverse effects can be increased when Methysergide is combined with Fluticasone propionate.
DB00593
The risk or severity of adverse effects can be increased when Methysergide is combined with Ethosuximide.
DB00599
The risk or severity of adverse effects can be increased when Methysergide is combined with Thiopental.
DB00647
The risk or severity of adverse effects can be increased when Methysergide is combined with Dextropropoxyphene.
DB00683
The risk or severity of adverse effects can be increased when Methysergide is combined with Midazolam.
DB00752
The risk or severity of adverse effects can be increased when Methysergide is combined with Tranylcypromine.
DB00754
The risk or severity of adverse effects can be increased when Methysergide is combined with Ethotoin.
DB00776
The risk or severity of adverse effects can be increased when Methysergide is combined with Oxcarbazepine.
DB00780
The risk or severity of adverse effects can be increased when Methysergide is combined with Phenelzine.
DB00802
The risk or severity of adverse effects can be increased when Methysergide is combined with Alfentanil.
DB00813
The risk or severity of adverse effects can be increased when Methysergide is combined with Fentanyl.
DB00818
The risk or severity of adverse effects can be increased when Methysergide is combined with Propofol.
DB00819
The risk or severity of adverse effects can be increased when Methysergide is combined with Acetazolamide.
DB00829
The risk or severity of adverse effects can be increased when Methysergide is combined with Diazepam.
DB00849
The risk or severity of adverse effects can be increased when Methysergide is combined with Methylphenobarbital.
DB00897
The risk or severity of adverse effects can be increased when Methysergide is combined with Triazolam.
DB00949
The risk or severity of adverse effects can be increased when Methysergide is combined with Felbamate.
DB01154
The risk or severity of adverse effects can be increased when Methysergide is combined with Thiamylal.
DB01221
The risk or severity of adverse effects can be increased when Methysergide is combined with Ketamine.
DB01351
The risk or severity of adverse effects can be increased when Methysergide is combined with Amobarbital.
DB01352
The risk or severity of adverse effects can be increased when Methysergide is combined with Aprobarbital.
DB01483
The risk or severity of adverse effects can be increased when Methysergide is combined with Barbital.
DB01587
The risk or severity of adverse effects can be increased when Methysergide is combined with Ketazolam.
DB06458
The risk or severity of adverse effects can be increased when Methysergide is combined with Remacemide.
DB08811
The risk or severity of adverse effects can be increased when Methysergide is combined with Tofisopam.
DB08815
The risk or severity of adverse effects can be increased when Methysergide is combined with Lurasidone.
DB09001
The risk or severity of adverse effects can be increased when Methysergide is combined with Barbexaclone.
DB09119
The risk or severity of adverse effects can be increased when Methysergide is combined with Eslicarbazepine acetate.
DB09241
The risk or severity of adverse effects can be increased when Methysergide is combined with Methylene blue.
DB14575
The risk or severity of adverse effects can be increased when Methysergide is combined with Eslicarbazepine.
DB12404
The risk or severity of adverse effects can be increased when Methysergide is combined with Remimazolam.
DB00751
The risk or severity of adverse effects can be increased when Methysergide is combined with Epinastine.
DB00604
The risk or severity of adverse effects can be increased when Methysergide is combined with Cisapride.
DB00315
Methysergide may increase the vasoconstricting activities of Zolmitriptan.
DB00669
Methysergide may increase the vasoconstricting activities of Sumatriptan.
DB00952
Methysergide may increase the vasoconstricting activities of Naratriptan.
DB00953
Methysergide may increase the vasoconstricting activities of Rizatriptan.
DB00998
Methysergide may increase the vasoconstricting activities of Frovatriptan.
DB05562
Methysergide may increase the vasoconstricting activities of Naluzotan.
DB08810
Methysergide may increase the vasoconstricting activities of Cinitapride.
DB11755
Methysergide may increase the vasoconstricting activities of Tetrahydrocannabivarin.
DB12361
Methysergide may increase the vasoconstricting activities of Piclozotan.
DB14010
Methysergide may increase the vasoconstricting activities of 5-methoxy-N,N-dimethyltryptamine.
DB00216
Eletriptan may increase the vasoconstricting activities of Methysergide.
DB01238
Methysergide may increase the vasoconstricting activities of Aripiprazole.
DB00589
Methysergide may increase the vasoconstricting activities of Lisuride.
DB00918
Methysergide may increase the vasoconstricting activities of Almotriptan.
DB04908
Methysergide may increase the vasoconstricting activities of Flibanserin.
DB06016
Methysergide may increase the vasoconstricting activities of Cariprazine.
DB06684
Methysergide may increase the vasoconstricting activities of Vilazodone.
DB09068
Methysergide may increase the vasoconstricting activities of Vortioxetine.
DB09128
Methysergide may increase the vasoconstricting activities of Brexpiprazole.
DB00248
Methysergide may increase the vasoconstricting activities of Cabergoline.
DB00320
Methysergide may increase the vasoconstricting activities of Dihydroergotamine.
DB00207
The serum concentration of Methysergide can be increased when it is combined with Azithromycin.
DB00877
The serum concentration of Sirolimus can be increased when it is combined with Methysergide.
DB01590
The serum concentration of Everolimus can be increased when it is combined with Methysergide.
DB06287
The serum concentration of Temsirolimus can be increased when it is combined with Methysergide.
DB01321
The serum concentration of Methysergide can be increased when it is combined with Josamycin.
DB11400
The serum concentration of Doramectin can be increased when it is combined with Methysergide.
DB00954
The serum concentration of Methysergide can be increased when it is combined with Dirithromycin.
DB01152
The serum concentration of Methysergide can be increased when it is combined with Candicidin.
DB01873
The serum concentration of Methysergide can be increased when it is combined with Epothilone D.
DB03010
The serum concentration of Methysergide can be increased when it is combined with Patupilone.
DB04070
The serum concentration of Methysergide can be increased when it is combined with 6-Deoxyerythronolide B.
DB04845
The serum concentration of Methysergide can be increased when it is combined with Ixabepilone.
DB05903
The serum concentration of Methysergide can be increased when it is combined with KOS-1584.
DB06233
The serum concentration of Methysergide can be increased when it is combined with Ridaforolimus.
DB06318
The serum concentration of Methysergide can be increased when it is combined with AVE9633.
DB06342
The serum concentration of Methysergide can be increased when it is combined with Coltuximab ravtansine.
DB06587
The serum concentration of Methysergide can be increased when it is combined with Mitemcinal.
DB07348
The serum concentration of Methysergide can be increased when it is combined with Brefeldin A.
DB09308
The serum concentration of Methysergide can be increased when it is combined with Solithromycin.
DB09309
The serum concentration of Methysergide can be increased when it is combined with Kitasamycin.
DB11383
The serum concentration of Methysergide can be increased when it is combined with Carbomycin.
DB11405
The serum concentration of Methysergide can be increased when it is combined with Eprinomectin.
DB11442
The serum concentration of Methysergide can be increased when it is combined with Oleandomycin.
DB11459
The serum concentration of Methysergide can be increased when it is combined with Selamectin.
DB11470
The serum concentration of Methysergide can be increased when it is combined with Tildipirosin.
DB11471
The serum concentration of Methysergide can be increased when it is combined with Tilmicosin.
DB11475
The serum concentration of Methysergide can be increased when it is combined with Tylosin.
DB11554
The serum concentration of Methysergide can be increased when it is combined with Tylvalosin.
DB11752
The serum concentration of Methysergide can be increased when it is combined with Bryostatin 1.
DB12089
The serum concentration of Methysergide can be increased when it is combined with Lorvotuzumab mertansine.
DB12266
The serum concentration of Methysergide can be increased when it is combined with Epofolate.
DB12391
The serum concentration of Methysergide can be increased when it is combined with Sagopilone.
DB12489
The serum concentration of Methysergide can be increased when it is combined with Mirvetuximab Soravtansine.
DB13287
The serum concentration of Methysergide can be increased when it is combined with Miocamycin.
DB13338
The serum concentration of Methysergide can be increased when it is combined with Flurithromycin.
DB13409
The serum concentration of Methysergide can be increased when it is combined with Rokitamycin.
DB13456
The serum concentration of Methysergide can be increased when it is combined with Midecamycin.
DB01190
The serum concentration of Methysergide can be increased when it is combined with Clindamycin.
DB13633
The serum concentration of Methysergide can be increased when it is combined with Mepartricin.
DB00230
The therapeutic efficacy of Methysergide can be increased when used in combination with Pregabalin.
DB11642
The serum concentration of Methysergide can be decreased when it is combined with Pitolisant.
DB13967
The risk or severity of hypotension can be increased when Patent Blue is combined with Methysergide.
DB04948
The therapeutic efficacy of Methysergide can be increased when used in combination with Lofexidine.
DB09046
The metabolism of Methysergide can be increased when combined with Metreleptin.
DB06413
The metabolism of Methysergide can be increased when combined with Armodafinil.
DB00615
The metabolism of Methysergide can be increased when combined with Rifabutin.
DB01645
The metabolism of Methysergide can be increased when combined with Genistein.
DB04911
The metabolism of Methysergide can be increased when combined with Oritavancin.
DB08909
The metabolism of Methysergide can be increased when combined with Glycerol phenylbutyrate.
DB09078
The metabolism of Methysergide can be increased when combined with Lenvatinib.
DB11560
The metabolism of Methysergide can be increased when combined with Lesinurad.
DB11586
The metabolism of Methysergide can be increased when combined with Asunaprevir.
DB11767
The metabolism of Methysergide can be increased when combined with Sarilumab.
DB00533
The metabolism of Rofecoxib can be increased when combined with Methysergide.
DB00812
The metabolism of Phenylbutazone can be increased when combined with Methysergide.
DB04817
The metabolism of Metamizole can be increased when combined with Methysergide.
DB00082
The metabolism of Methysergide can be increased when combined with Pegvisomant.
DB00136
The metabolism of Methysergide can be increased when combined with Calcitriol.
DB00163
The metabolism of Methysergide can be increased when combined with Vitamin E.
DB00180
The metabolism of Methysergide can be increased when combined with Flunisolide.
DB00197
The metabolism of Methysergide can be increased when combined with Troglitazone.
DB00301
The metabolism of Methysergide can be increased when combined with Flucloxacillin.
DB00316
The metabolism of Methysergide can be increased when combined with Acetaminophen.
DB00338
The metabolism of Methysergide can be increased when combined with Omeprazole.
DB00357
The metabolism of Methysergide can be increased when combined with Aminoglutethimide.
DB00394
The metabolism of Methysergide can be increased when combined with Beclomethasone dipropionate.
DB00396
The metabolism of Methysergide can be increased when combined with Progesterone.
DB00400
The metabolism of Methysergide can be increased when combined with Griseofulvin.
DB00439
The metabolism of Methysergide can be increased when combined with Cerivastatin.
DB00443
The metabolism of Methysergide can be increased when combined with Betamethasone.
DB00448
The metabolism of Methysergide can be increased when combined with Lansoprazole.
DB00485
The metabolism of Methysergide can be increased when combined with Dicloxacillin.
DB00591
The metabolism of Methysergide can be increased when combined with Fluocinolone acetonide.
DB00602
The metabolism of Methysergide can be increased when combined with Ivermectin.
DB00603
The metabolism of Methysergide can be increased when combined with Medroxyprogesterone acetate.
DB00620
The metabolism of Methysergide can be increased when combined with Triamcinolone.
DB00624
The metabolism of Methysergide can be increased when combined with Testosterone.
DB00636
The metabolism of Methysergide can be increased when combined with Clofibrate.
DB00701
The metabolism of Methysergide can be increased when combined with Amprenavir.
DB00741
The metabolism of Methysergide can be increased when combined with Hydrocortisone.
DB00769
The metabolism of Methysergide can be increased when combined with Hydrocortamate.
DB00857
The metabolism of Methysergide can be increased when combined with Terbinafine.
DB00860
The metabolism of Methysergide can be increased when combined with Prednisolone.
DB00957
The metabolism of Methysergide can be increased when combined with Norgestimate.
DB00959
The metabolism of Methysergide can be increased when combined with Methylprednisolone.
DB01011
The metabolism of Methysergide can be increased when combined with Metyrapone.
DB01030
The metabolism of Methysergide can be increased when combined with Topotecan.
DB01032
The metabolism of Methysergide can be increased when combined with Probenecid.
DB01083
The metabolism of Methysergide can be increased when combined with Orlistat.
DB01115
The metabolism of Methysergide can be increased when combined with Nifedipine.
DB01138
The metabolism of Methysergide can be increased when combined with Sulfinpyrazone.
DB01201
The metabolism of Methysergide can be increased when combined with Rifapentine.
DB01222
The metabolism of Methysergide can be increased when combined with Budesonide.
DB01285
The metabolism of Methysergide can be increased when combined with Corticotropin.
DB01333
The metabolism of Methysergide can be increased when combined with Cefradine.
DB01380
The metabolism of Methysergide can be increased when combined with Cortisone acetate.
DB01384
The metabolism of Methysergide can be increased when combined with Paramethasone.
DB01394
The metabolism of Methysergide can be increased when combined with Colchicine.
DB01609
The metabolism of Methysergide can be increased when combined with Deferasirox.
DB04905
The metabolism of Methysergide can be increased when combined with Tesmilifene.
DB04920
The metabolism of Methysergide can be increased when combined with Clevidipine.
DB06708
The metabolism of Methysergide can be increased when combined with Lumefantrine.
DB06717
The metabolism of Methysergide can be increased when combined with Fosaprepitant.
DB06739
The metabolism of Methysergide can be increased when combined with Seratrodast.
DB08905
The metabolism of Methysergide can be increased when combined with Formestane.
DB08906
The metabolism of Methysergide can be increased when combined with Fluticasone furoate.
DB08911
The metabolism of Methysergide can be increased when combined with Trametinib.
DB08970
The metabolism of Methysergide can be increased when combined with Fluprednidene.
DB09383
The metabolism of Methysergide can be increased when combined with Meprednisone.
DB11487
The metabolism of Methysergide can be increased when combined with Dexamethasone isonicotinate.
DB11921
The metabolism of Methysergide can be increased when combined with Deflazacort.
DB13003
The metabolism of Methysergide can be increased when combined with Cortivazol.
DB13208
The metabolism of Methysergide can be increased when combined with Prednylidene.
DB13843
The metabolism of Methysergide can be increased when combined with Cloprednol.
DB13867
The metabolism of Methysergide can be increased when combined with Fluticasone.
DB13943
The metabolism of Methysergide can be increased when combined with Testosterone cypionate.
DB13944
The metabolism of Methysergide can be increased when combined with Testosterone enanthate.
DB13952
The metabolism of Methysergide can be increased when combined with Estradiol acetate.
DB13953
The metabolism of Methysergide can be increased when combined with Estradiol benzoate.
DB13954
The metabolism of Methysergide can be increased when combined with Estradiol cypionate.
DB13955
The metabolism of Methysergide can be increased when combined with Estradiol dienanthate.
DB13956
The metabolism of Methysergide can be increased when combined with Estradiol valerate.
DB14512
The metabolism of Methysergide can be increased when combined with Mometasone furoate.
DB14539
The metabolism of Methysergide can be increased when combined with Hydrocortisone acetate.
DB14545
The metabolism of Methysergide can be increased when combined with Hydrocortisone succinate.
DB14631
The metabolism of Methysergide can be increased when combined with Prednisolone phosphate.
DB14633
The metabolism of Methysergide can be increased when combined with Prednisolone hemisuccinate.
DB14644
The metabolism of Methysergide can be increased when combined with Methylprednisolone hemisuccinate.
DB14646
The metabolism of Methysergide can be increased when combined with Prednisone acetate.
DB14652
The metabolism of Methysergide can be increased when combined with Clocortolone acetate.
DB14659
The metabolism of Methysergide can be increased when combined with Melengestrol acetate.
DB14669
The metabolism of Methysergide can be increased when combined with Betamethasone phosphate.
DB14681
The metabolism of Methysergide can be increased when combined with Cortisone.
DB01013
The metabolism of Methysergide can be increased when combined with Clobetasol propionate.
DB01047
The metabolism of Methysergide can be increased when combined with Fluocinonide.
DB14540
The metabolism of Methysergide can be increased when combined with Hydrocortisone butyrate.
DB00764
The metabolism of Methysergide can be increased when combined with Mometasone.
DB15822
The metabolism of Methysergide can be increased when combined with Pralsetinib.
DB08971
The metabolism of Methysergide can be increased when combined with Fluocortolone.
DB11750
The metabolism of Methysergide can be increased when combined with Clobetasol.
DB15566
The metabolism of Methysergide can be increased when combined with Prednisolone acetate.
DB09095
The metabolism of Methysergide can be increased when combined with Difluocortolone.
DB00243
The metabolism of Methysergide can be decreased when combined with Ranolazine.
DB00501
The metabolism of Methysergide can be decreased when combined with Cimetidine.
DB01016
The metabolism of Methysergide can be decreased when combined with Glyburide.
DB01259
The metabolism of Methysergide can be decreased when combined with Lapatinib.
DB01369
The metabolism of Methysergide can be decreased when combined with Quinupristin.
DB01764
The metabolism of Methysergide can be decreased when combined with Dalfopristin.
DB04839
The metabolism of Methysergide can be decreased when combined with Cyproterone acetate.
DB04894
The metabolism of Methysergide can be decreased when combined with Vapreotide.
DB05928
The metabolism of Methysergide can be decreased when combined with Dovitinib.
DB06663
The metabolism of Methysergide can be decreased when combined with Pasireotide.
DB06791
The metabolism of Methysergide can be decreased when combined with Lanreotide.
DB08820
The metabolism of Methysergide can be decreased when combined with Ivacaftor.
DB08864
The metabolism of Methysergide can be decreased when combined with Rilpivirine.
DB09099
The metabolism of Methysergide can be decreased when combined with Somatostatin.
DB11837
The metabolism of Methysergide can be decreased when combined with Osilodrostat.
DB12332
The metabolism of Methysergide can be decreased when combined with Rucaparib.
DB13879
The metabolism of Methysergide can be decreased when combined with Glecaprevir.
DB13941
The metabolism of Methysergide can be decreased when combined with Piperaquine.
DB04794
The metabolism of Methysergide can be decreased when combined with Bifonazole.
DB00678
The metabolism of Losartan can be decreased when combined with Methysergide.
DB01023
The metabolism of Felodipine can be decreased when combined with Methysergide.
DB01029
The metabolism of Irbesartan can be decreased when combined with Methysergide.
DB01275
The metabolism of Hydralazine can be decreased when combined with Methysergide.
DB01388
The metabolism of Mibefradil can be decreased when combined with Methysergide.
DB06268
The metabolism of Sitaxentan can be decreased when combined with Methysergide.
DB09235
The metabolism of Efonidipine can be decreased when combined with Methysergide.
DB00353
The metabolism of Methylergometrine can be decreased when combined with Methysergide.
DB01628
The metabolism of Etoricoxib can be decreased when combined with Methysergide.
DB00041
The metabolism of Methysergide can be decreased when combined with Aldesleukin.
DB00254
The metabolism of Methysergide can be decreased when combined with Doxycycline.
DB00255
The metabolism of Methysergide can be decreased when combined with Diethylstilbestrol.
DB00317
The metabolism of Methysergide can be decreased when combined with Gefitinib.
DB00358
The metabolism of Methysergide can be decreased when combined with Mefloquine.
DB00435
The metabolism of Methysergide can be decreased when combined with Nitric Oxide.
DB00446
The metabolism of Methysergide can be decreased when combined with Chloramphenicol.
DB00481
The metabolism of Methysergide can be decreased when combined with Raloxifene.
DB00549
The metabolism of Methysergide can be decreased when combined with Zafirlukast.
DB00627
The metabolism of Methysergide can be decreased when combined with Niacin.
DB00681
The metabolism of Methysergide can be decreased when combined with Amphotericin B.
DB00759
The metabolism of Methysergide can be decreased when combined with Tetracycline.
DB00845
The metabolism of Methysergide can be decreased when combined with Clofazimine.
DB00916
The metabolism of Methysergide can be decreased when combined with Metronidazole.
DB01015
The metabolism of Methysergide can be decreased when combined with Sulfamethoxazole.
DB01059
The metabolism of Methysergide can be decreased when combined with Norfloxacin.
DB01071
The metabolism of Methysergide can be decreased when combined with Mequitazine.
DB01085
The metabolism of Methysergide can be decreased when combined with Pilocarpine.
DB01093
The metabolism of Methysergide can be decreased when combined with Dimethyl sulfoxide.
DB01095
The metabolism of Methysergide can be decreased when combined with Fluvastatin.
DB01129
The metabolism of Methysergide can be decreased when combined with Rabeprazole.
DB01204
The metabolism of Methysergide can be decreased when combined with Mitoxantrone.
DB01685
The metabolism of Methysergide can be decreased when combined with Topiroxostat.
DB01698
The metabolism of Methysergide can be decreased when combined with Rutin.
DB02709
The metabolism of Methysergide can be decreased when combined with Resveratrol.
DB05482
The metabolism of Methysergide can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
DB05814
The metabolism of Methysergide can be decreased when combined with GPI-1485.
DB06174
The metabolism of Methysergide can be decreased when combined with Noscapine.
DB06370
The metabolism of Methysergide can be decreased when combined with Indisulam.
DB06412
The metabolism of Methysergide can be decreased when combined with Oxymetholone.
DB06469
The metabolism of Methysergide can be decreased when combined with Lestaurtinib.
DB06774
The metabolism of Methysergide can be decreased when combined with Capsaicin.
DB08816
The metabolism of Methysergide can be decreased when combined with Ticagrelor.
DB11198
The metabolism of Methysergide can be decreased when combined with Peppermint oil.
DB11574
The metabolism of Methysergide can be decreased when combined with Elbasvir.
DB11805
The metabolism of Methysergide can be decreased when combined with Saracatinib.
DB12010
The metabolism of Methysergide can be decreased when combined with Fostamatinib.
DB12070
The metabolism of Methysergide can be decreased when combined with Letermovir.
DB12245
The metabolism of Methysergide can be decreased when combined with Triclabendazole.
DB12532
The metabolism of Methysergide can be decreased when combined with Oxetacaine.
DB13975
The metabolism of Methysergide can be decreased when combined with Black cohosh.
DB14009
The metabolism of Methysergide can be decreased when combined with Medical Cannabis.
DB14635
The metabolism of Methysergide can be decreased when combined with Curcumin sulfate.
DB00104
The metabolism of Methysergide can be decreased when combined with Octreotide.
DB00694
The metabolism of Methysergide can be decreased when combined with Daunorubicin.
DB00619
The metabolism of Methysergide can be decreased when combined with Imatinib.
DB00204
The metabolism of Methysergide can be decreased when combined with Dofetilide.
DB00277
The metabolism of Theophylline can be decreased when combined with Methysergide.
DB00946
The metabolism of Phenprocoumon can be decreased when combined with Methysergide.
DB01008
The metabolism of Busulfan can be decreased when combined with Methysergide.
DB01223
The metabolism of Aminophylline can be decreased when combined with Methysergide.
DB01396
The metabolism of Digitoxin can be decreased when combined with Methysergide.
DB01418
The metabolism of Acenocoumarol can be decreased when combined with Methysergide.
DB09289
The metabolism of Tianeptine can be decreased when combined with Methysergide.
DB08910
The metabolism of Pomalidomide can be decreased when combined with Methysergide.
DB08865
The metabolism of Methysergide can be decreased when combined with Crizotinib.
DB05239
The metabolism of Cobimetinib can be decreased when combined with Methysergide.
DB11963
The metabolism of Dacomitinib can be decreased when combined with Methysergide.
DB12371
The metabolism of Siponimod can be decreased when combined with Methysergide.
DB00682
The metabolism of Warfarin can be decreased when combined with Methysergide.
DB00540
The metabolism of Nortriptyline can be decreased when combined with Methysergide.
DB00908
The metabolism of Quinidine can be decreased when combined with Methysergide.
DB01100
The metabolism of Pimozide can be decreased when combined with Methysergide.
DB01227
The metabolism of Levacetylmethadol can be decreased when combined with Methysergide.
DB01242
The metabolism of Clomipramine can be decreased when combined with Methysergide.
DB00091
The metabolism of Methysergide can be decreased when combined with Cyclosporine.
DB04855
The metabolism of Dronedarone can be decreased when combined with Methysergide.
DB08912
The metabolism of Methysergide can be decreased when combined with Dabrafenib.
DB11581
The metabolism of Methysergide can be decreased when combined with Venetoclax.
DB12015
The metabolism of Methysergide can be decreased when combined with Alpelisib.
DB00531
The metabolism of Methysergide can be decreased when combined with Cyclophosphamide.
DB00570
The metabolism of Methysergide can be decreased when combined with Vinblastine.
DB00675
The metabolism of Methysergide can be decreased when combined with Tamoxifen.
DB00773
The metabolism of Methysergide can be decreased when combined with Etoposide.
DB01181
The metabolism of Methysergide can be decreased when combined with Ifosfamide.
DB01229
The metabolism of Methysergide can be decreased when combined with Paclitaxel.
DB08881
The metabolism of Methysergide can be decreased when combined with Vemurafenib.
DB09330
The metabolism of Methysergide can be decreased when combined with Osimertinib.
DB12267
The metabolism of Methysergide can be decreased when combined with Brigatinib.
DB13874
The metabolism of Methysergide can be decreased when combined with Enasidenib.
DB14568
The metabolism of Methysergide can be decreased when combined with Ivosidenib.
DB00864
The metabolism of Methysergide can be decreased when combined with Tacrolimus.
DB01128
The metabolism of Methysergide can be decreased when combined with Bicalutamide.
DB01254
The metabolism of Methysergide can be decreased when combined with Dasatinib.
DB06589
The metabolism of Methysergide can be decreased when combined with Pazopanib.
DB08827
The metabolism of Methysergide can be decreased when combined with Lomitapide.
DB09063
The metabolism of Methysergide can be decreased when combined with Ceritinib.
DB09073
The metabolism of Methysergide can be decreased when combined with Palbociclib.
DB09074
The metabolism of Methysergide can be decreased when combined with Olaparib.
DB11703
The metabolism of Methysergide can be decreased when combined with Acalabrutinib.
DB00398
The metabolism of Methysergide can be decreased when combined with Sorafenib.
DB00444
The metabolism of Methysergide can be decreased when combined with Teniposide.
DB00530
The metabolism of Methysergide can be decreased when combined with Erlotinib.
DB00637
The metabolism of Methysergide can be decreased when combined with Astemizole.
DB00997
The metabolism of Methysergide can be decreased when combined with Doxorubicin.
DB01118
The metabolism of Methysergide can be decreased when combined with Amiodarone.
DB01248
The metabolism of Methysergide can be decreased when combined with Docetaxel.
DB01268
The metabolism of Methysergide can be decreased when combined with Sunitinib.
DB05773
The metabolism of Methysergide can be decreased when combined with Trastuzumab emtansine.
DB06616
The metabolism of Methysergide can be decreased when combined with Bosutinib.
DB08870
The metabolism of Methysergide can be decreased when combined with Brentuximab vedotin.
DB08896
The metabolism of Methysergide can be decreased when combined with Regorafenib.
DB00563
The metabolism of Methotrexate can be decreased when combined with Methysergide.
DB00361
The metabolism of Vinorelbine can be decreased when combined with Methysergide.
DB00541
The metabolism of Vincristine can be decreased when combined with Methysergide.
DB04572
The metabolism of Thiotepa can be decreased when combined with Methysergide.
DB05109
The metabolism of Trabectedin can be decreased when combined with Methysergide.
DB05294
The metabolism of Vandetanib can be decreased when combined with Methysergide.
DB11363
The metabolism of Alectinib can be decreased when combined with Methysergide.
DB11641
The metabolism of Vinflunine can be decreased when combined with Methysergide.
DB15035
The metabolism of Zanubrutinib can be decreased when combined with Methysergide.
DB00188
The metabolism of Bortezomib can be decreased when combined with Methysergide.
DB00309
The metabolism of Vindesine can be decreased when combined with Methysergide.
DB06603
The metabolism of Panobinostat can be decreased when combined with Methysergide.
DB06626
The metabolism of Axitinib can be decreased when combined with Methysergide.
DB08877
The metabolism of Ruxolitinib can be decreased when combined with Methysergide.
DB08901
The metabolism of Ponatinib can be decreased when combined with Methysergide.
DB09054
The metabolism of Idelalisib can be decreased when combined with Methysergide.
DB09143
The metabolism of Sonidegib can be decreased when combined with Methysergide.
DB09570
The metabolism of Ixazomib can be decreased when combined with Methysergide.
DB11828
The metabolism of Neratinib can be decreased when combined with Methysergide.
DB11986
The metabolism of Entrectinib can be decreased when combined with Methysergide.
DB12147
The metabolism of Erdafitinib can be decreased when combined with Methysergide.
DB12483
The metabolism of Copanlisib can be decreased when combined with Methysergide.
DB12978
The metabolism of Pexidartinib can be decreased when combined with Methysergide.
DB00762
The metabolism of Irinotecan can be decreased when combined with Methysergide.
DB06176
The metabolism of Romidepsin can be decreased when combined with Methysergide.
DB06212
The metabolism of Tolvaptan can be decreased when combined with Methysergide.
DB11817
The metabolism of Baricitinib can be decreased when combined with Methysergide.
DB12001
The metabolism of Abemaciclib can be decreased when combined with Methysergide.
DB06772
The metabolism of Cabazitaxel can be decreased when combined with Methysergide.
DB00186
The metabolism of Methysergide can be decreased when combined with Lorazepam.
DB00191
The metabolism of Methysergide can be decreased when combined with Phentermine.
DB00208
The metabolism of Methysergide can be decreased when combined with Ticlopidine.
DB00264
The metabolism of Metoprolol can be decreased when combined with Methysergide.
DB00426
The metabolism of Famciclovir can be decreased when combined with Methysergide.
DB00433
The metabolism of Prochlorperazine can be decreased when combined with Methysergide.
DB00518
The metabolism of Albendazole can be decreased when combined with Methysergide.
DB00567
The metabolism of Cephalexin can be decreased when combined with Methysergide.
DB00590
The metabolism of Doxazosin can be decreased when combined with Methysergide.
DB00717
The metabolism of Norethisterone can be decreased when combined with Methysergide.
DB01039
The metabolism of Fenofibrate can be decreased when combined with Methysergide.
DB01098
The metabolism of Rosuvastatin can be decreased when combined with Methysergide.
DB01395
The metabolism of Drospirenone can be decreased when combined with Methysergide.
DB01411
The metabolism of Pranlukast can be decreased when combined with Methysergide.
DB01431
The metabolism of Allylestrenol can be decreased when combined with Methysergide.
DB01624
The metabolism of Zuclopenthixol can be decreased when combined with Methysergide.
DB01656
The metabolism of Roflumilast can be decreased when combined with Methysergide.
DB06218
The metabolism of Lacosamide can be decreased when combined with Methysergide.
DB06480
The metabolism of Prucalopride can be decreased when combined with Methysergide.
DB09030
The metabolism of Vorapaxar can be decreased when combined with Methysergide.
DB09071
The metabolism of Tasimelteon can be decreased when combined with Methysergide.
DB09079
The metabolism of Nintedanib can be decreased when combined with Methysergide.
DB09299
The metabolism of Tenofovir alafenamide can be decreased when combined with Methysergide.
DB11094
The metabolism of Vitamin D can be decreased when combined with Methysergide.
DB11273
The metabolism of Dihydroergocornine can be decreased when combined with Methysergide.
DB11742
The metabolism of Ebastine can be decreased when combined with Methysergide.
DB11952
The metabolism of Duvelisib can be decreased when combined with Methysergide.
DB12515
The metabolism of 9-aminocamptothecin can be decreased when combined with Methysergide.
DB12887
The metabolism of Tazemetostat can be decreased when combined with Methysergide.
DB12952
The metabolism of Methylprednisone can be decreased when combined with Methysergide.
DB13345
The metabolism of Dihydroergocristine can be decreased when combined with Methysergide.
DB13385
The metabolism of Dihydroergocryptine can be decreased when combined with Methysergide.
DB14126
The metabolism of Tenofovir can be decreased when combined with Methysergide.
DB15444
The metabolism of Elexacaftor can be decreased when combined with Methysergide.
DB12825
The metabolism of Lefamulin can be decreased when combined with Methysergide.
DB05077
The risk or severity of adverse effects can be increased when SLV319 is combined with Methysergide.
DB06155
The risk or severity of adverse effects can be increased when Rimonabant is combined with Methysergide.
DB06624
The risk or severity of adverse effects can be increased when Taranabant is combined with Methysergide.
DB09061
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Methysergide.
DB11903
The risk or severity of adverse effects can be increased when GW842166 is combined with Methysergide.
DB12193
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Methysergide.
DB12649
The risk or severity of adverse effects can be increased when Ibipinabant is combined with Methysergide.
DB13070
The risk or severity of adverse effects can be increased when Surinabant is combined with Methysergide.
DB13950
The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Methysergide.
DB14011
The risk or severity of adverse effects can be increased when Nabiximols is combined with Methysergide.
DB14043
The risk or severity of adverse effects can be increased when Palmidrol is combined with Methysergide.
DB14737
The risk or severity of adverse effects can be increased when Cannabinol is combined with Methysergide.
DB12141
The therapeutic efficacy of Methysergide can be decreased when used in combination with Gilteritinib.
DB12927
The therapeutic efficacy of Theodrenaline can be decreased when used in combination with Methysergide.
DB13917
The therapeutic efficacy of Deoxyepinephrine can be decreased when used in combination with Methysergide.
DB06273
The metabolism of Methysergide can be increased when combined with Tocilizumab.
DB09036
The metabolism of Methysergide can be increased when combined with Siltuximab.
DB00005
The metabolism of Methysergide can be increased when combined with Etanercept.
DB00026
The metabolism of Methysergide can be increased when combined with Anakinra.
DB00051
The metabolism of Methysergide can be increased when combined with Adalimumab.
DB00065
The metabolism of Methysergide can be increased when combined with Infliximab.
DB01281
The metabolism of Methysergide can be increased when combined with Abatacept.
DB04956
The metabolism of Methysergide can be increased when combined with Afelimomab.
DB05676
The metabolism of Methysergide can be increased when combined with Apremilast.
DB06168
The metabolism of Methysergide can be increased when combined with Canakinumab.
DB06372
The metabolism of Methysergide can be increased when combined with Rilonacept.
DB06674
The metabolism of Methysergide can be increased when combined with Golimumab.
DB08904
The metabolism of Methysergide can be increased when combined with Certolizumab pegol.
DB09029
The metabolism of Methysergide can be increased when combined with Secukinumab.
DB14724
The metabolism of Methysergide can be increased when combined with Emapalumab.
DB00024
Thyrotropin alfa may increase the vasoconstricting activities of Methysergide.
DB00279
Liothyronine may increase the vasoconstricting activities of Methysergide.
DB03604
Tiratricol may increase the vasoconstricting activities of Methysergide.
DB09100
Thyroid, porcine may increase the vasoconstricting activities of Methysergide.
DB01583
Liotrix may increase the vasoconstricting activities of Methysergide.
DB00451
Levothyroxine may increase the vasoconstricting activities of Methysergide.
DB00199
Erythromycin may increase the vasoconstricting activities of Methysergide.
DB00778
Roxithromycin may increase the vasoconstricting activities of Methysergide.
DB00976
Telithromycin may increase the vasoconstricting activities of Methysergide.
DB06419
Cethromycin may increase the vasoconstricting activities of Methysergide.
DB11823
The risk or severity of hypertension can be increased when Esketamine is combined with Methysergide.
DB00395
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Methysergide.
DB14754
The risk or severity of hypertension can be increased when Solriamfetol is combined with Methysergide.
DB13946
Testosterone undecanoate may increase the hypertensive activities of Methysergide.
DB00281
The risk or severity of hypertension can be increased when Methysergide is combined with Lidocaine.
DB00402
The risk or severity of CNS depression can be increased when Methysergide is combined with Eszopiclone.
DB00575
The risk or severity of sedation can be increased when Clonidine is combined with Methysergide.
DB00924
The risk or severity of CNS depression can be increased when Methysergide is combined with Cyclobenzaprine.
DB01233
The risk or severity of sedation can be increased when Metoclopramide is combined with Methysergide.
DB11732
The risk or severity of adverse effects can be increased when Methysergide is combined with Lasmiditan.
DB06119
The serum concentration of Methysergide can be decreased when it is combined with Cenobamate.
DB00193
The risk or severity of CNS depression can be increased when Methysergide is combined with Tramadol.
DB00246
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methysergide.
DB01601
The serum concentration of Lopinavir can be increased when it is combined with Methysergide.
DB00503
The serum concentration of Methysergide can be increased when it is combined with Ritonavir.
DB00502
The risk or severity of CNS depression can be increased when Haloperidol is combined with Methysergide.
DB11652
The metabolism of Tucatinib can be decreased when combined with Methysergide.
DB00472
Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Methysergide.
DB11932
The serum concentration of Methysergide can be increased when it is combined with Abametapir.
DB14881
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Methysergide is combined with Oliceridine.
DB15762
The serum concentration of Methysergide can be decreased when it is combined with Satralizumab.

序列

实验性质

Melting Point
195 °C
PhysProp
logP
1.5

外部标识符

resource：Drugs Product Database (DPD)
identifier：5187
resource：ChEBI
identifier：584020
resource：PubChem Compound
identifier：6540428
resource：PubChem Substance
identifier：46506117
resource：KEGG Compound
identifier：C07199
resource：KEGG Drug
identifier：D02357
resource：ChemSpider
identifier：5022813
resource：BindingDB
identifier：50031942
resource：PharmGKB
identifier：PA164743265
resource：Therapeutic Targets Database
identifier：DAP000366
resource：IUPHAR
identifier：134
resource：Guide to Pharmacology
identifier：134
resource：Wikipedia
identifier：Methysergide
resource：ChEMBL
identifier：CHEMBL485253
resource：RxCUI
identifier：6911

外部链接

RxList
http://www.rxlist.com/cgi/generic3/sansert.htm

路径

目标

id:BE0000393
name:5-hydroxytryptamine receptor 2B
organism:Humans
action:antagonist
Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H: Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci. 1996 May;8(5):959-67.
known-action:yes
name:5-hydroxytryptamine receptor 2B
general-function:Serotonin receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain. Plays a role in the regulation of behavior, including impulsive behavior. Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine.
gene-name:HTR2B
locus:2q36.3-q37.1
cellular-location:Cell membrane
transmembrane-regions:57-79 91-113 130-151 172-192 217-239 325-345 361-382
signal-regions:
theoretical-pi:9.47
molecular-weight:54297.41
chromosome-location:2
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5294GenAtlasHTR2BGenBank Gene DatabaseX77307GenBank Protein Database475198IUPHAR7Guide to Pharmacology7UniProtKBP41595UniProt Accession5HT2B_HUMAN
synonyms:5-HT-2BSerotonin receptor 2B
amino-acid-sequence:>lcl|BSEQ0016078|5-hydroxytryptamine receptor 2B MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALL ILMVIIPTIGGNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAM WPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVW LISIGIAIPVPIKGIETDVDNPNNITCVLTKERFGDFMLFGSLAAFFTPLAIMIVTYFLT IHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEKVAMLDGSRKDKALPNSGDET LMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLCDSCNQTTLQM LLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNP MAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSY V
gene-sequence:>lcl|BSEQ0016079|5-hydroxytryptamine receptor 2B (HTR2B) ATGGCTCTCTCTTACAGAGTGTCTGAACTTCAAAGCACAATTCCTGAGCACATTTTGCAG AGCACCTTTGTTCACGTTATCTCTTCTAACTGGTCTGGATTACAGACAGAATCAATACCA GAGGAAATGAAACAGATTGTTGAGGAACAGGGAAATAAACTGCACTGGGCAGCTCTTCTG ATACTCATGGTGATAATACCCACAATTGGTGGAAATACCCTTGTTATTCTGGCTGTTTCA CTGGAGAAGAAGCTGCAGTATGCTACTAATTACTTTCTAATGTCCTTGGCGGTGGCTGAT TTGCTGGTTGGATTGTTTGTGATGCCAATTGCCCTCTTGACAATAATGTTTGAGGCTATG TGGCCCCTCCCACTTGTTCTATGTCCTGCCTGGTTATTTCTTGACGTTCTCTTTTCAACC GCATCCATCATGCATCTCTGTGCCATTTCAGTGGATCGTTACATAGCCATCAAAAAGCCA ATCCAGGCCAATCAATATAACTCACGGGCTACAGCATTCATCAAGATTACAGTGGTGTGG TTAATTTCAATAGGCATTGCCATTCCAGTCCCTATTAAAGGGATAGAGACTGATGTGGAC AACCCAAACAATATCACTTGTGTGCTGACAAAGGAACGTTTTGGCGATTTCATGCTCTTT GGCTCACTGGCTGCCTTCTTCACACCTCTTGCAATTATGATTGTCACCTACTTTCTCACT ATCCATGCTTTACAGAAGAAGGCTTACTTAGTCAAAAACAAGCCACCTCAACGCCTAACA TGGTTGACTGTGTCTACAGTTTTCCAAAGGGATGAAACACCTTGCTCGTCACCGGAAAAG GTGGCAATGCTGGATGGTTCTCGAAAGGACAAGGCTCTGCCCAACTCAGGTGATGAAACA CTTATGCGAAGAACATCCACAATTGGGAAAAAGTCAGTGCAGACCATTTCCAACGAACAG AGAGCCTCAAAGGTCCTAGGGATTGTGTTTTTCCTCTTTTTGCTTATGTGGTGTCCCTTC TTTATTACAAATATAACTTTAGTTTTATGTGATTCCTGTAACCAAACTACTCTCCAAATG CTCCTGGAGATATTTGTGTGGATAGGCTATGTTTCCTCAGGAGTGAATCCTTTGGTCTAC ACCCTCTTCAATAAGACATTTCGGGATGCATTTGGCCGATATATCACCTGCAATTACCGG GCCACAAAGTCAGTAAAAACTCTCAGAAAACGCTCCAGTAAGATCTACTTCCGGAATCCA ATGGCAGAGAACTCTAAGTTTTTCAAGAAACATGGAATTCGAAATGGGATTAACCCTGCC ATGTACCAGAGTCCAATGAGGCTCCGAAGTTCAACCATTCAGTCTTCATCAATCATTCTA CTAGATACGCTTCTCCTCACTGAAAATGAAGGTGACAAAACTGAAGAGCAAGTTAGTTAT GTATAG
pfams:PF000017tm_1
go-classifiers:componentcell junctioncomponentcytoplasmcomponentdendritecomponentintegral component of plasma membranecomponentneuronal cell bodycomponentplasma membranecomponentsynapsefunctiondrug bindingfunctionG-protein alpha-subunit bindingfunctionGTPase activator activityfunctionserotonin bindingfunctionserotonin receptor activityprocessactivation of phospholipase C activityprocessbehaviorprocesscalcium-mediated signalingprocesscardiac muscle hypertrophyprocesscellular calcium ion homeostasisprocesscellular response to amine stimulusprocesscellular response to serotoninprocesscellular response to temperature stimulusprocesscGMP biosynthetic processprocessembryonic morphogenesisprocessERK1 and ERK2 cascadeprocessG-protein coupled receptor internalizationprocessG-protein coupled receptor signaling pathwayprocessheart morphogenesisprocesshepatic stellate cell activationprocessinositol phosphate metabolic processprocessintestine smooth muscle contractionprocession transmembrane transportprocessnegative regulation of apoptotic processprocessnegative regulation of autophagyprocessnegative regulation of cell deathprocessneural crest cell differentiationprocessneural crest cell migrationprocessphosphatidylinositol 3-kinase signalingprocessphosphorylationprocesspositive regulation of cell divisionprocesspositive regulation of cell proliferationprocesspositive regulation of cytokine productionprocesspositive regulation of cytokine secretionprocesspositive regulation of endothelial cell proliferationprocesspositive regulation of ERK1 and ERK2 cascadeprocesspositive regulation of I-kappaB kinase/NF-kappaB signalingprocesspositive regulation of MAP kinase activityprocesspositive regulation of nitric-oxide synthase activityprocesspositive regulation of phosphatidylinositol biosynthetic processprocessprotein kinase C signalingprocessprotein kinase C-activating G-protein coupled receptor signaling pathwayprocessregulation of behaviorprocessrelease of sequestered calcium ion into cytosolprocessresponse to drugprocessserotonin receptor signaling pathwayprocessvasoconstriction
id:BE0000533
name:5-hydroxytryptamine receptor 2C
organism:Humans
action:antagonist
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Johnson MP, Lea RA, Curtain RP, MacMillan JC, Griffiths LR: An investigation of the 5-HT2C receptor gene as a migraine candidate gene. Am J Med Genet B Neuropsychiatr Genet. 2003 Feb;117B(1):86-9.
known-action:yes
name:5-hydroxytryptamine receptor 2C
general-function:Serotonin receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.
gene-name:HTR2C
locus:Xq24
cellular-location:Cell membrane
transmembrane-regions:53-78 90-110 128-150 171-193 214-235 312-333 349-371
signal-regions:1-32
theoretical-pi:9.11
molecular-weight:51820.705
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5295GenAtlasHTR2CGenBank Gene DatabaseM81778GenBank Protein Database338028IUPHAR8Guide to Pharmacology8UniProtKBP28335UniProt Accession5HT2C_HUMAN
synonyms:5-HT-1C5-HT-2C5-HT1C5-hydroxytryptamine receptor 1CHTR1CSerotonin receptor 2C
amino-acid-sequence:>lcl|BSEQ0001064|5-hydroxytryptamine receptor 2C MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV
gene-sequence:>lcl|BSEQ0010373|5-hydroxytryptamine receptor 2C (HTR2C) ATGGTGAACCTGAGGAATGCGGTGCATTCATTCCTTGTGCACCTAATTGGCCTATTGGTT TGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACC TCCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATC GTCATCATAATAATCATGACAATAGGTGGCAACATCCTTGTGATCATGGCAGTAAGCATG GAAAAGAAACTGCACAATGCCACCAATTACTTCTTAATGTCCCTAGCCATTGCTGATATG CTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCTGGCAATCCTTTATGATTATGTCTGG CCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTTTATTTTCAACAGCG TCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAGCAATACGTAATCCTATT GAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCA ATTTCTATAGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTG TTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTC GTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTT CTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGT CTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCT AACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATG CAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTT CTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCC TGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGT TCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCC AACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGA GTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAAT GAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAAT TTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGA
pfams:PF000017tm_1
go-classifiers:componentcytosolcomponentintegral component of plasma membranecomponentplasma membranefunction1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine bindingfunctiondrug bindingfunctionGq/11-coupled serotonin receptor activityfunctionserotonin bindingfunctionserotonin receptor activityprocessbehavioral fear responseprocesscellular calcium ion homeostasisprocesscGMP biosynthetic processprocessfeeding behaviorprocesslocomotory behaviorprocessphospholipase C-activating G-protein coupled receptor signaling pathwayprocessphospholipase C-activating serotonin receptor signaling pathwayprocesspositive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathwayprocesspositive regulation of ERK1 and ERK2 cascadeprocesspositive regulation of fat cell differentiationprocesspositive regulation of phosphatidylinositol biosynthetic processprocessregulation of appetiteprocessregulation of corticotropin-releasing hormone secretionprocessregulation of neurological system processprocessrelease of sequestered calcium ion into cytosolprocessresponse to drugprocessserotonin receptor signaling pathwayprocesssynaptic transmission
id:BE0000451
name:5-hydroxytryptamine receptor 2A
organism:Humans
action:antagonist
Castilho VM, Avanzi V, Brandao ML: Antinociception elicited by aversive stimulation of the inferior colliculus. Pharmacol Biochem Behav. 1999 Mar;62(3):425-31.
Geerts IS, Matthys KE, Herman AG, Bult H: Involvement of 5-HT1B receptors in collar-induced hypersensitivity to 5-hydroxytryptamine of the rabbit carotid artery. Br J Pharmacol. 1999 Jul;127(6):1327-36.
Shaw AM, Brown C, Irvine J, Bunton DC, MacDonald A: Role of the 5-HT(2A)receptor and alpha(1)-adrenoceptor in the contractile response of rat pulmonary artery to 5-HT in the presence and absence of nitric oxide. Pulm Pharmacol Ther. 2000;13(6):277-85.
Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA: Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. Br J Pharmacol. 2001 Nov;134(6):1351-9.
Connor JD, Rasheed H, Gilani AH, Cheema M, Rizvi Z, Saeed SA: Second messengers in platelet aggregation evoked by serotonin and A23187, a calcium ionophore. Life Sci. 2001 Oct 26;69(23):2759-64.
Robert A. Davidoff (2002). Migraine : Manifestations, Pathogenesis, and Management (pp. 438). Oxford University Press.
known-action:yes
name:5-hydroxytryptamine receptor 2A
general-function:Virus receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.
gene-name:HTR2A
locus:13q14-q21
cellular-location:Cell membrane
transmembrane-regions:76-99 111-132 149-171 192-215 234-254 325-346 363-384
signal-regions:
theoretical-pi:7.72
molecular-weight:52602.58
chromosome-location:13
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5293GenAtlasHTR2AGenBank Gene DatabaseS42168GenBank Protein Database36431IUPHAR6Guide to Pharmacology6UniProtKBP28223UniProt Accession5HT2A_HUMAN
synonyms:5-HT-2HTR2Serotonin receptor 2A
amino-acid-sequence:>lcl|BSEQ0000899|5-hydroxytryptamine receptor 2A MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGC LSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD MLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNP IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF VSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIH REPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGA LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV
gene-sequence:>lcl|BSEQ0020465|5-hydroxytryptamine receptor 2A (HTR2A) ATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTCAACTACGAACTCCCTAATGCAA TTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACTCCGGAGAAGCTAACACTTCT GATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCCTGTGAAGGGTGC CTCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGGTCTGCTTTACTG ACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTCATCATGGCAGTGTCC CTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGTCACTTGCCATAGCTGAT ATGCTGCTGGGTTTCCTTGTCATGCCCGTGTCCATGTTAACCATCCTGTATGGGTACCGG TGGCCTCTGCCGAGCAAGCTTTGTGCAGTCTGGATTTACCTGGACGTGCTCTTCTCCACG GCCTCCATCATGCACCTCTGCGCCATCTCGCTGGACCGCTACGTCGCCATCCAGAATCCC ATCCACCACAGCCGCTTCAACTCCAGAACTAAGGCATTTCTGAAAATCATTGCTGTTTGG ACCATATCAGTAGGTATATCCATGCCAATACCAGTCTTTGGGCTACAGGACGATTCGAAG GTCTTTAAGGAGGGGAGTTGCTTACTCGCCGATGATAACTTTGTCCTGATCGGCTCTTTT GTGTCATTTTTCATTCCCTTAACCATCATGGTGATCACCTACTTTCTAACTATCAAGTCA CTCCAGAAAGAAGCTACTTTGTGTGTAAGTGATCTTGGCACACGGGCCAAATTAGCTTCT TTCAGCTTCCTCCCTCAGAGTTCTTTGTCTTCAGAAAAGCTCTTCCAGCGGTCGATCCAT AGGGAGCCAGGGTCCTACACAGGCAGGAGGACTATGCAGTCCATCAGCAATGAGCAAAAG GCATGCAAGGTGCTGGGCATCGTCTTCTTCCTGTTTGTGGTGATGTGGTGCCCTTTCTTC ATCACAAACATCATGGCCGTCATCTGCAAAGAGTCCTGCAATGAGGATGTCATTGGGGCC CTGCTCAATGTGTTTGTTTGGATCGGTTATCTCTCTTCAGCAGTCAACCCACTAGTCTAC ACACTGTTCAACAAGACCTATAGGTCAGCCTTTTCACGGTATATTCAGTGTCAGTACAAG GAAAACAAAAAACCATTGCAGTTAATTTTAGTGAACACAATACCGGCTTTGGCCTACAAG TCTAGCCAACTTCAAATGGGACAAAAAAAGAATTCAAAGCAAGATGCCAAGACAACAGAT AATGACTGCTCAATGGTTGCTCTAGGAAAGCAGCATTCTGAAGAGGCTTCTAAAGACAAT AGCGACGGAGTGAATGAAAAGGTGAGCTGTGTGTGA
pfams:PF000017tm_1
go-classifiers:componentaxoncomponentcaveolacomponentcell body fibercomponentcytoplasmic membrane-bounded vesiclecomponentcytosolcomponentdendritic shaftcomponentintegral component of plasma membranecomponentneuronal cell bodycomponentplasma membranefunction1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine bindingfunctiondrug bindingfunctionserotonin bindingfunctionserotonin receptor activityfunctionvirus receptor activityprocessactivation of phospholipase C activityprocessagingprocessartery smooth muscle contractionprocessbehavioral response to cocaineprocesscell deathprocesscellular calcium ion homeostasisprocessdetection of mechanical stimulus involved in sensory perception of painprocessdetection of temperature stimulus involved in sensory perception of painprocessmemoryprocessnegative regulation of potassium ion transportprocessnegative regulation of synaptic transmission, glutamatergicprocessphosphatidylinositol 3-kinase signalingprocessphospholipase C-activating serotonin receptor signaling pathwayprocesspositive regulation of cell proliferationprocesspositive regulation of ERK1 and ERK2 cascadeprocesspositive regulation of fat cell differentiationprocesspositive regulation of glycolytic processprocesspositive regulation of MAP kinase activityprocesspositive regulation of peptidyl-tyrosine phosphorylationprocesspositive regulation of phosphatidylinositol biosynthetic processprocesspositive regulation of vasoconstrictionprocessprotein localization to cytoskeletonprocessregulation of behaviorprocessregulation of dopamine secretionprocessregulation of hormone secretionprocessrelease of sequestered calcium ion into cytosolprocessresponse to drugprocessserotonin receptor signaling pathwayprocesssleepprocesssynaptic transmissionprocesstemperature homeostasisprocessurinary bladder smooth muscle contraction
id:BE0000291
name:5-hydroxytryptamine receptor 1A
organism:Humans
action:agonist
Scrogin KE, Johnson AK, Brooks VL: Methysergide delays the decompensatory responses to severe hemorrhage by activating 5-HT(1A) receptors. Am J Physiol Regul Integr Comp Physiol. 2000 Nov;279(5):R1776-86.
Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9.
Sugimoto Y, Inoue K, Yamada J: Involvement of 5-HT(2) receptor in imipramine-induced hyperglycemia in mice. Horm Metab Res. 2003 Sep;35(9):511-6.
Skyba DA, Radhakrishnan R, Rohlwing JJ, Wright A, Sluka KA: Joint manipulation reduces hyperalgesia by activation of monoamine receptors but not opioid or GABA receptors in the spinal cord. Pain. 2003 Nov;106(1-2):159-68.
Pranzatelli MR, Balletti J: Characterization of 5-hydroxytryptamine 1A-like binding sites in human ganglioneuroblastoma. Neurosci Lett. 1991 Oct 28;132(1):117-20.
known-action:yes
name:5-hydroxytryptamine receptor 1A
general-function:Serotonin receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.
gene-name:HTR1A
locus:5q11.2-q13
cellular-location:Cell membrane
transmembrane-regions:37-62 74-98 111-132 153-178 192-217 346-367 379-403
signal-regions:
theoretical-pi:9.05
molecular-weight:46106.335
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5286GenAtlasHTR1AGenBank Gene DatabaseM28269GenBank Protein Database189928IUPHAR1Guide to Pharmacology1UniProtKBP08908UniProt Accession5HT1A_HUMAN
synonyms:5-HT-1AADRB2RL1ADRBRL1G-21Serotonin receptor 1A
amino-acid-sequence:>lcl|BSEQ0018934|5-hydroxytryptamine receptor 1A MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCC TSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGN SKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLP FFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC RQ
gene-sequence:>lcl|BSEQ0018935|5-hydroxytryptamine receptor 1A (HTR1A) ATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTCCCTTTGAG ACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGATCACCTCT CTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGGTGGCTGCC ATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTTTGGCGGTC ACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGGTGCTCAAC AAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGCTGTGCTGC ACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCATCACGGAC CCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCTCGCTCACT TGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCCCGGAAGAC CGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCTATTCCACC TTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCATATTCCGA GCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAGCGGACACC CGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGTCGGGGAGC AGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCAATGGCGCG GTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAGTGGGCAAC TCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCCCCGCCTCT TTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGGCCCGAGAG AGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCTGGCTGCCC TTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGCCCACCCTG TTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCGTCATTTAC GCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTAAGTTCTGC CGCCAGTGA
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentplasma membranefunctionserotonin receptor activityprocessadenylate cyclase-inhibiting serotonin receptor signaling pathwayprocessbehavioral fear responseprocesscell proliferationprocessexploration behaviorprocessG-protein coupled receptor signaling pathwayprocesspositive regulation of cell proliferationprocessregulation of behaviorprocessregulation of dopamine metabolic processprocessregulation of hormone secretionprocessregulation of serotonin secretionprocessserotonin metabolic processprocessserotonin receptor signaling pathwayprocessvasoconstriction
id:BE0000650
name:5-hydroxytryptamine receptor 7
organism:Humans
action:antagonist
Sugimoto Y, Inoue K, Yamada J: The tricyclic antidepressant clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9.
known-action:yes
name:5-hydroxytryptamine receptor 7
general-function:Serotonin receptor activity
specific-function:This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
gene-name:HTR7
locus:10q21-q24
cellular-location:Cell membrane
transmembrane-regions:84-104 118-138 158-178 202-222 237-257 326-346 368-388
signal-regions:
theoretical-pi:8.97
molecular-weight:53554.43
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5302GenAtlasHTR7GenBank Gene DatabaseU68487GenBank Protein Database1857143IUPHAR12Guide to Pharmacology12UniProtKBP34969UniProt Accession5HT7R_HUMAN
synonyms:5-HT-75-HT-XSerotonin receptor 7
amino-acid-sequence:>lcl|BSEQ0001296|5-hydroxytryptamine receptor 7 MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTW DAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLI VSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDR YLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYT IYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVE ECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSC IPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALK LAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD
gene-sequence:>lcl|BSEQ0010453|5-hydroxytryptamine receptor 7 (HTR7) ATGATGGACGTTAACAGCAGCGGCCGCCCGGACCTCTACGGGCACCTCCGCTCTTTCCTT CTGCCAGAAGTGGGGCGCGGGCTGCCCGACTTGAGCCCCGACGGTGGCGCCGACCCGGTC GCGGGCTCCTGGGCGCCGCACCTGCTGAGCGAGGTGACAGCCAGCCCGGCGCCCACCTGG GACGCGCCCCCGGACAATGCCTCCGGCTGTGGGGAACAGATCAACTACGGCAGAGTCGAG AAAGTTGTGATCGGCTCCATCCTGACGCTCATCACGCTGCTGACGATCGCGGGCAACTGC CTGGTGGTGATCTCCGTGTGCTTCGTCAAGAAGCTCCGCCAGCCCTCCAACTACCTGATC GTGTCCCTGGCGCTGGCCGACCTCTCGGTGGCTGTGGCGGTCATGCCCTTCGTCAGCGTC ACCGACCTCATCGGGGGCAAGTGGATCTTTGGACACTTTTTCTGTAATGTCTTCATCGCC ATGGACGTCATGTGCTGCACGGCCTCGATCATGACCCTGTGCGTGATCAGCATTGACAGG TACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCG AAGATGATTCTCTCCGTCTGGCTTCTCTCCGCCTCCATCACCTTACCTCCACTCTTTGGA TGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACG ATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTAC CAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGA GTGGAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAA GAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAG CGAGAACAGAAAGCAGCCACCACCCTGGGGATCATCGTCGGGGCCTTTACCGTGTGCTGG CTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGCAGCTGC ATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAAC CCTTTTATATATGCCTTCTTCAACCGGGACCTGAGGACCACCTATCGCAGCCTGCTCCAG TGCCAGTACCGGAATATCAACCGGAAGCTCTCAGCTGCAGGCATGCATGAAGCCCTGAAG CTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCTACAAAATGCTGACTACTGTAGAAAA AAAGGTCATGATTCATGA
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentplasma membranefunctionserotonin receptor activityprocessblood circulationprocesscircadian rhythmprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessserotonin receptor signaling pathwayprocesssmooth muscle contractionprocesssynaptic transmissionprocessvasoconstriction
id:BE0000797
name:5-hydroxytryptamine receptor 1B
organism:Humans
action:binder
Matsumoto I, Combs MR, Jones DJ: Characterization of 5-hydroxytryptamine1B receptors in rat spinal cord via [125I]iodocyanopindolol binding and inhibition of [3H]-5-hydroxytryptamine release. J Pharmacol Exp Ther. 1992 Feb;260(2):614-26.
Saxena PR, Tfel-Hansen P (2005). Triptans, 5-HT 1B/1D receptor agonists in the acute treatment of migraines. In Headaches (3rd ed., pp. 469-503, 459-467). Lippincott Williams & Wilkins.
known-action:unknown
name:5-hydroxytryptamine receptor 1B
general-function:Serotonin receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries.
gene-name:HTR1B
locus:6q13
cellular-location:Cell membrane
transmembrane-regions:50-75 85-110 124-145 166-187 206-228 316-336 350-371
signal-regions:
theoretical-pi:8.82
molecular-weight:43567.535
chromosome-location:6
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5287GenAtlasHTR1BGenBank Gene DatabaseD10995GenBank Protein Database219679IUPHAR2Guide to Pharmacology2UniProtKBP28222UniProt Accession5HT1B_HUMAN
synonyms:5-HT-1B5-HT-1D-betaHTR1DBS12Serotonin 1D beta receptorSerotonin receptor 1B
amino-acid-sequence:>lcl|BSEQ0019014|5-hydroxytryptamine receptor 1B MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALIT LATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQV VCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISI SLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRIL KQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLE KKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYL NSLINPIIYTMSNEDFKQAFHKLIRFKCTS
gene-sequence:>lcl|BSEQ0019015|5-hydroxytryptamine receptor 1B (HTR1B) ATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGAGACCTGGGTT CCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGACTACATTTAC CAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGCGCTCATCACC TTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAAACTG CACACCCCGGCTAACTACCTGATCGCCTCTCTGGCGGTCACCGACCTGCTTGTGTCCATC CTGGTGATGCCCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACTGGGCCAGGTG GTCTGTGACTTCTGGCTGTCGTCGGACATCACTTGTTGCACTGCCTCCATCCTGCACCTC TGTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTACTCAGCTAAA AGGACTCCCAAGAGGGCGGCGGTCATGATCGCGCTGGTGTGGGTCTTCTCCATCTCTATC TCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGGTGTCGGAATGCGTG GTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGTGGGTGCTTTCTACTTCCCC ACCCTGCTCCTCATCGCCCTCTATGGCCGCATCTACGTAGAAGCCCGCTCCCGGATTTTG AAACAGACGCCCAACAGGACCGGCAAGCGCTTGACCCGAGCCCAGCTGATAACCGACTCC CCCGGGTCCACGTCCTCGGTCACCTCTATTAACTCGCGGGTTCCCGACGTGCCCAGCGAA TCCGGATCTCCTGTGTATGTGAACCAAGTCAAAGTGCGAGTCTCCGACGCCCTGCTGGAA AAGAAGAAACTCATGGCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGGGATCATTTTG GGAGCCTTTATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGATGCCTATCTGC AAAGATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTC AACTCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAAACAAGCATTC CATAAACTGATACGTTTTAAGTGCACAAGTTGA
pfams:PF000017tm_1
go-classifiers:componentcytoplasmcomponentintegral component of plasma membranecomponentplasma membranefunctiondrug bindingfunctionserotonin bindingfunctionserotonin receptor activityprocessadenylate cyclase-inhibiting serotonin receptor signaling pathwayprocessbone remodelingprocesscellular response to alkaloidprocesscellular response to drugprocesscellular response to temperature stimulusprocessdrinking behaviorprocessG-protein coupled receptor internalizationprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessnegative regulation of cAMP biosynthetic processprocessnegative regulation of serotonin secretionprocessnegative regulation of synaptic transmission, GABAergicprocessnegative regulation of synaptic transmission, glutamatergicprocessprotein kinase C-activating G-protein coupled receptor signaling pathwayprocessregulation of behaviorprocessregulation of dopamine secretionprocessresponse to cocaineprocessresponse to ethanolprocessresponse to mineralocorticoidprocesssynaptic transmissionprocessvasoconstriction
id:BE0000460
name:5-hydroxytryptamine receptor 1F
organism:Humans
action:binder
Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA: Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
Saxena PR, Tfel-Hansen P (2005). Triptans, 5-HT 1B/1D receptor agonists in the acute treatment of migraines. In Headaches (3rd ed., pp. 469-503, 459-467). Lippincott Williams & Wilkins.
known-action:unknown
name:5-hydroxytryptamine receptor 1F
general-function:Serotonin receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
gene-name:HTR1F
locus:3p12
cellular-location:Cell membrane
transmembrane-regions:30-50 61-83 98-118 141-161 179-201 291-311 330-350
signal-regions:
theoretical-pi:9.08
molecular-weight:41708.505
chromosome-location:3
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5292GenAtlasHTR1FGenBank Gene DatabaseL05597GenBank Protein Database307420IUPHAR5Guide to Pharmacology5UniProtKBP30939UniProt Accession5HT1F_HUMAN
synonyms:5-HT-1FHTR1ELSerotonin receptor 1F
amino-acid-sequence:>lcl|BSEQ0010323|5-hydroxytryptamine receptor 1F MDFLNSSDQNLTSEELLNRMPSKILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHPANY LICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALD RYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIV STIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKS VSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILG AFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQK LVRCRC
gene-sequence:>lcl|BSEQ0010324|5-hydroxytryptamine receptor 1F (HTR1F) ATGGATTTCTTAAATTCATCTGATCAAAACTTGACCTCAGAGGAACTGTTAAACAGAATG CCATCCAAAATTCTGGTGTCCCTCACTCTGTCTGGGCTGGCACTGATGACAACAACTATC AACTCCCTTGTGATCGCTGCAATTATTGTGACCCGGAAGCTGCACCATCCAGCCAATTAT TTAATTTGTTCCCTTGCAGTCACAGATTTTCTTGTGGCTGTCCTGGTGATGCCCTTCAGC ATTGTGTATATTGTGAGAGAGAGCTGGATTATGGGGCAAGTGGTCTGTGACATTTGGCTG AGTGTTGACATTACCTGCTGCACGTGCTCCATCTTGCATCTCTCAGCTATAGCTTTGGAT CGGTATCGAGCAATCACAGATGCTGTTGAGTATGCCAGGAAAAGGACTCCAAAGCATGCT GGCATTATGATTACAATAGTTTGGATTATATCTGTTTTTATCTCTATGCCTCCTCTATTC TGGAGGCACCAAGGAACTAGCAGAGATGATGAATGCATCATCAAGCACGACCACATTGTT TCCACCATTTACTCAACATTTGGAGCTTTCTACATCCCACTGGCATTGATTTTGATCCTT TACTACAAAATATATAGAGCAGCAAAGACATTATACCACAAGAGACAAGCAAGTAGGATT GCAAAGGAGGAGGTGAATGGCCAAGTCCTTTTGGAGAGTGGTGAGAAAAGCACTAAATCA GTTTCCACATCCTATGTACTAGAAAAGTCTTTATCTGACCCATCAACAGACTTTGATAAA ATTCATAGCACAGTGAGAAGTCTCAGGTCTGAATTCAAGCATGAGAAATCTTGGAGAAGG CAAAAGATCTCAGGTACAAGAGAACGGAAAGCAGCCACTACCCTGGGATTAATCTTGGGT GCATTTGTAATATGTTGGCTTCCTTTTTTTGTAAAAGAATTAGTTGTTAATGTCTGTGAC AAATGTAAAATTTCTGAAGAAATGTCCAATTTTTTGGCATGGCTTGGGTATCTCAATTCC CTTATAAATCCACTGATTTACACAATCTTTAATGAAGACTTCAAGAAAGCATTCCAAAAG CTTGTGCGATGTCGATGTTAG
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentplasma membranefunctionserotonin bindingfunctionserotonin receptor activityprocessadenylate cyclase-inhibiting G-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessserotonin receptor signaling pathwayprocesssynaptic transmission
id:BE0000476
name:5-hydroxytryptamine receptor 1E
organism:Humans
action:binder
Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA: Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
known-action:unknown
name:5-hydroxytryptamine receptor 1E
general-function:Serotonin receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
gene-name:HTR1E
locus:6q14-q15
cellular-location:Cell membrane
transmembrane-regions:23-47 60-82 97-118 139-159 180-202 292-314 325-347
signal-regions:
theoretical-pi:8.98
molecular-weight:41681.57
chromosome-location:6
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5291GenAtlasHTR1EGenBank Gene DatabaseM91467GenBank Protein Database177774IUPHAR4Guide to Pharmacology4UniProtKBP28566UniProt Accession5HT1E_HUMAN
synonyms:5-HT-1ES31Serotonin receptor 1E
amino-acid-sequence:>lcl|BSEQ0010335|5-hydroxytryptamine receptor 1E MNITNCTTEASMAIRPKTITEKMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQPANYL ICSLAVTDLLVAVLVMPLSIIYIVMDRWKLGYFLCEVWLSVDMTCCTCSILHLCVIALDR YWAITNAIEYARKRTAKRAALMILTVWTISIFISMPPLFWRSHRRLSPPPSQCTIQHDHV IYTIYSTLGAFYIPLTLILILYYRIYHAAKSLYQKRGSSRHLSNRSTDSQNSFASCKLTQ TFCVSDFSTSDPTTEFEKFHASIRIPPFDNDLDHPGERQQISSTRERKAARILGLILGAF ILSWLPFFIKELIVGLSIYTVSSEVADFLTWLGYVNSLINPLLYTSFNEDFKLAFKKLIR CREHT
gene-sequence:>lcl|BSEQ0010336|5-hydroxytryptamine receptor 1E (HTR1E) ATGAACATCACAAACTGTACCACAGAGGCCAGCATGGCTATAAGACCCAAGACCATCACT GAGAAGATGCTCATTTGCATGACTCTGGTGGTCATCACCACCCTCACCACGTTGCTGAAC TTGGCTGTGATCATGGCTATTGGCACCACCAAGAAGCTCCACCAGCCTGCCAACTACCTA ATCTGTTCTCTGGCCGTGACGGACCTCCTGGTGGCAGTGCTCGTCATGCCCCTGAGCATC ATCTACATTGTCATGGATCGCTGGAAGCTTGGGTACTTCCTCTGTGAGGTGTGGCTGAGT GTGGACATGACCTGCTGCACCTGCTCCATCCTCCACCTCTGTGTCATTGCCCTGGACAGG TACTGGGCCATCACCAATGCTATTGAATACGCCAGGAAGAGGACGGCCAAGAGGGCCGCG CTGATGATCCTTACCGTCTGGACCATCTCCATTTTCATCTCCATGCCCCCTCTGTTCTGG AGAAGCCACCGCCGCCTAAGCCCTCCCCCTAGTCAGTGCACCATCCAGCACGACCATGTT ATCTACACCATTTACTCCACGCTGGGTGCGTTTTATATCCCCTTGACTTTGATACTGATT CTCTATTACCGGATTTACCACGCGGCCAAGAGCCTTTACCAGAAAAGGGGATCAAGTCGG CACTTAAGCAACAGAAGCACAGATAGCCAGAATTCTTTTGCAAGTTGTAAACTTACACAG ACTTTCTGTGTGTCTGACTTCTCCACCTCAGACCCTACCACAGAGTTTGAAAAGTTCCAT GCCTCCATCAGGATCCCCCCCTTCGACAATGATCTAGATCACCCAGGAGAACGTCAGCAG ATCTCTAGCACCAGGGAACGGAAGGCAGCACGCATCCTGGGGCTGATTCTGGGTGCATTC ATTTTATCCTGGCTGCCATTTTTCATCAAAGAGTTGATTGTGGGTCTGAGCATCTACACC GTGTCCTCGGAAGTGGCCGACTTTCTGACGTGGCTCGGTTATGTGAATTCTCTGATCAAC CCTCTGCTCTATACGAGTTTTAATGAAGACTTTAAGCTGGCTTTTAAAAAGCTCATTAGA TGCCGAGAGCATACTTAG
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentplasma membranefunctionG-protein coupled receptor activityfunctionserotonin bindingfunctionserotonin receptor activityprocessadenylate cyclase-inhibiting G-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessnegative regulation of cAMP metabolic processprocessserotonin receptor signaling pathwayprocesssynaptic transmission

酶

BE0002638Cytochrome P450 3A4HumanssubstrateT243978-1-4614-7495-1Marcucci C., Hutchens M., Wittwer E., Weingarten T., Sprung J., Nicholson W., Lalwani K., Metro D., Dull R., Swide C., Seagull F., Kirsch J. and Sandson N. (2015). A case approach to perioperative drug-drug interactions. Springer.noCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic process

载体

运输工具

药物反应

效应

不良反应